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List of abbreviations and symbols
19F MRS fluorine-19 magnetic resonance spectroscopy
3D CSI three-dimensional chemical shift imaging
5-FU 5-fluorouracil
A FU anabolites
A/C ratio of anabolites to catabolites
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A/T ratio of anabolites to total fluorine-containing compounds
ATC aspartate transcarbamylase
AUC area under the concentration-time curve
Bo magnetic field
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CH2THF W5,W10-methylenetetrahydrofolate
Cmax maximum peak area
CR complete remission
d distance
DHFR dihydrofolate reductase
DHFU 5,6-dihydro-5-fluorouracil
dMRI dynamic MRI
dMRI dynamic magnetic resonance imaging
DPD dihydropyrimidine dehydrogenase
dTTP deoxythymidine triphosphate
F 5-FU
F- fluoride anions
FBAL a-fluoro-G-alanine
FdUMP 5-fluoro-2’-deoxyuridine 5’-monophosphate
FdUrd 5-fluoro-2’-deoxyuridine
FdUTP 5-fluoro-2’-deoxyuridine 5’-triphosphate
FID free induction decay
Fnucs fluoronucleosides
Fnuct fluoronucleotides
FPGS folylpolyglutamate synthase
FUMP 5-fluorouridine 5'-monophosphate
FUPA a-fluoro-G-ureidopropionic acid
FUrd 5-fluorouridine
FUTP 5-fluorouridine 5’-triphosphate
Gd-DTPA gadolinium diethylenetriaminepentaacetic acid
GDF growth delay factor
hr high resolution
i.p. intraperitoneally
i.v. intravenous
IFN a -interferon
LV leucovorin
M magnetic moments
MR magnetic resonance
MRI MR imaging
MRS magnetic resonance spectroscopy
MTX methotrexate
NMR nuclear magnetic resonance
OPRTase orotate phosphoribosyltransferase
PALA W-(phosphonacetyl)-L-aspartate
PCA perchloric acid
PCr phosphocreatine
PD progressive disease
PET positron emission tomography
PF perfusion fraction
PFCE perfluorochemical emulsions
Pi inorganic phosphate
ppm parts per million
PR partial response
PRPP 5-phosphoribosyl-pyrophosphate
RF radiofrequency
s.c. subcutaneously
S.D. standard deviation
SD stable disease
sd standard deviation
SE standard error of the mean
T Tesla
T total fluorine-containing compounds
tl/2 half-life
TA acquisition time
TD tumour doubling time
to onset of enhancement
TE echo time
THF tetrahydrofolate
TK thymidine kinase
TMTX trimetrexate glucuronate
TP thymidine phosphorylase
TR repetition time
TS thymidylate synthase
VARPRO variable projection method
Vm volume of metastases
a-IFN a-interferon
General introduction
Y vonne J.L. Kamm
Department of Medical Oncology, University Medical Centre Nijmegen,
the Netherlands
Chapter 1
Introduction
After lung cancer in men and breast cancer in women, colorectal cancer is the 
third most common cancer in the western world. Half of the patients with 
colorectal cancer will get metastases and die. Since its introduction in 1957 by 
Heidelberger, 5-fluorouracil or 5-FU is still the most important cytotoxic drug to 
treat advanced colorectal cancer [1]. However, response percentages are only 
15-20%. To evaluate the treatment results of chemotherapy, conventional 
radiographic techniques are used. Over the last decades much has been 
learned about the working mechanism of 5-FU, but still the question remains 
whether in a certain patient a treatment regimen will be effective or not.
In Fig. 1-1 the major features of the metabolism of 5-FU are shown 
schematically. 5-FU can be converted into anabolites, of which some are 
important for its therapeutic effect, or degraded to catabolites. The anabolites 
consist of the fluoronucleosides (FNucs) 5-fluorouridine (FUrd) and 5-fluoro-2’- 
deoxyuridine (FdUrd), and of the fluoronucleotides (FNuct) of which 5-fluoro-2’- 
deoxyuridine 5’-monophosphate (FdUMP), 5-fluoro-2’-deoxyuridine 5’- 
triphosphate (FdUTP) and 5-fluorouridine 5’-triphosphate (FUTP) are most 
important for the cytotoxic effect of 5-FU. The main catabolites are 5,6-dihydro- 
5-fluorouracil (DHFU), a-fluoro-G-ureidopropionic acid (FUPA) and a-fluoro-R- 
alanine (FBAL). The metabolic pathways can be affected by modulators (see Fig. 
1-1), which are agents that can enhance the effect of a drug such as 5-FU.
A better insight in the in vivo pharmacokinetics of 5-FU is important to 
understand and modify the treatment efficacy of this drug. An attractive method 
to study 5-FU uptake and retention and its metabolism both in vitro and in vivo is
19F magnetic resonance spectroscopy (MRS) [2]. For the work described in this
19thesis F MRS was selected as the main tool to monitor 5-FU and its 
conversions in tumour tissue.
14
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Fig. 1 -1. Schematic overview of 5-FU metabolism and its modulation.
+, stimulation; -, inhibition; FNucs, fluoronucleosides; FNuct, fluoronucleotides; FdUMP, 5- 
fluoro-2'-deoxyuridine 5'-monophosphate; FdUTP, 5-fluoro-2'-deoxyuridine 5'- 
triphosphate; FUTP, 5-fluorouridine 5'-triphosphate; DHFU, 5,6-dihydro-5-fluorouracil; 
FUPA, a-fluoro-ft-ureidopropionic acid; FBAL, a-fluoro-B-alanine; F-, fluoride anions.
One of the most important features of MR from the clinical point of view is that it 
can be performed in a non-invasive way, which is obviously a major advantage 
for the direct investigation of human subjects. In addition, also important 
information can be gathered from the study of body fluids, cell cultures, tissue
15
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extracts, isolated tissues, and animal models. Examples of the complementary
19nature of such investigations will be given under the section of F MR.
In this chapter some basic aspects of magnetic resonance (MR) are briefly 
described, in particular those relevant for the application of MR spectroscopy
19and imaging in the work for this thesis. In addition, F MRS is discussed with 
special emphasis on its role in studying the pharmacokinetics of 5-FU. Finally,
19an overview is given of in vitro and in vivo F MRS studies performed on 
(colorectal) tumour tissue, in animals and in humans.
Magnetic resonance
Purcell and Bloch and colleagues [3,4] first discovered the phenomenon of 
nuclear magnetic resonance (NMR) in 1946. It lasted 20 years until the 
technique became accessible to biochemists, mostly because of the advent of 
Fourier transform NMR [5]. Medical applications of NMR, more commonly 
abbreviated as MR, commenced in the late 1970’s. MR is often distinguished in 
MR imaging (MRI) and spectroscopy (MRS). MRI is based primary on the 
detection of signals from water, whereas MRS is used for the detection of 
metabolites. MR combines spatial and chemical information. MRI is not only a 
method of obtaining diagnostic radiological images, it can also provide 
physiological information. The first MR image was demonstrated in 1977 [6], 
while the first clinical demonstration of in vivo MR spectroscopy occurred in 1981 
[7].
Essential particles in a MR experiment are the positively charged nuclei of 
atoms. Only nuclei with an odd number of protons demonstrate a net spin [2,8]. 
This can be considered as a spinning motion of the nucleus about its own axis. 
The combination of charge and spin results in a magnetic moment, which is
1 31 13specific to that nucleus. Nuclei often employed in biomedical MR are H, P, C
and 19F.
16
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If a sample is placed in a magnetic field, the magnetic moments of the nuclei will 
tend to align themselves with or against the direction of the external magnetic 
field. The spin up and spin down states represent a low energy level of the 
nucleus (with the field direction) and a high energy level (opposite to the field 
direction). A transition between the two states can be induced by radiofrequency 
(RF) radiation at the Larmor frequency, having energy equal to the difference 
between these two energy levels. Initially the vector sum of the magnetic 
moments (M) of the nuclei is oriented in the same direction as the external 
magnetic field (B0), which is labelled as the z (or vertical) axis. If a suitable RF 
pulse tips this sum moment into the horizontal (xy) plane, the net moment will 
precess in that plane. This can be recorded as an oscillating signal. The 
envelope of the signal will show an exponential reduction as the horizontal 
components of M dephase and gradually cancel each other out. This damped 
signal is known as the free induction decay (FID). The Fourier transform 
converts this time signal to a signal in the frequency domain. The application of 
different RF pulses and RF acquisition schemes in combination with the use of 
magnetic field gradients are used to produce MR images or spectra.
MR imaging
In MR imaging the MR signals provide information about the spatial distribution
1
of water within a sample. The MR most sensitive nucleus of water is H. MR data 
are collected with a range of different field gradient conditions in order to obtain 
information in two or three dimensions. The signal is displayed as a two­
dimensional cross-sectional image, in which the brightness of each element 
represents signal intensity. The signal intensities are influenced not only by the 
tissue level of H2O, but also by the effect of different relaxation processes on its 
signal. Certain contrast agents, like diethylenetriaminepentaacetic acid (Gd- 
DTPA), cause a shortening of the relaxation times of the surrounding water
17
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proton spins and are used as MR contrast media. As Gd-DTPA is an 
extracellular contrast agent, enhancement is obtained by the presence of the 
agent in microvessels and in the extracellular extravascular space. Most 
malignant tumours develop abnormal (neo)vascularisation and show earlier and 
faster enhancement with dynamic MRI compared with normal tissue [9]. These 
differences in enhancement are most conspicuous in the early-dynamic, first­
pass phase of contrast uptake. Therefore, fast imaging sequences (i.e. 1 image /
2 s), uncovering the first-pass of the contrast agent through the vascular system, 
are often used. In Fig. 1-2 results of a dynamic MRI examination are shown. In 
Fig. 7-3A of chapter 7 this figure is printed in color.
Fig. 1-2. Dynamic contrast-enhanced MR image of patients’ liver with metastases. Liver 
metastasis shows a faster contrast uptake enhancement than surrounding liver tissue. 1, 
liver metastasis; 2, normal liver tissue; 3, right kidney; 4, left kidney; 5, spleen;
6, artefact of stomach movement; 7, enhancement band of aorta flow.
18
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MR spectroscopy
Different MR sensitive nuclei have characteristic Larmor precession frequencies, 
determined by their gyromagnetic ratio and the magnetic field strength. In 
addition, different (bio)chemical environments of a particular isotope induce 
characteristic small ‘chemical shifts’ in frequency compared with a reference 
frequency, expressed in terms of the dimensionless units of parts per million 
(ppm). By measuring the different frequencies, the different chemical 
environments of an isotope provide a compound spectral ‘fingerprint’ from which
19this compound can be identified. In Fig. 1-3 a F MR spectrum is shown from 5- 
FU and its anabolites as an illustration.
In MR spectroscopy the frequency of different signals in the spectra provides 
chemical information and is used for the detection of metabolites. Only 
molecules, which are free to tumble, give a peak, which is sharp enough to be 
detected above the random noise in the baseline [10]. This restricts the signals 
observed to (water) soluble metabolites. Small differences in biochemical 
environment can cause clustering of different metabolite signals in the same 
region of the spectrum. In spectra obtained in vivo (intact animal, cell) peaks are 
broader than of compounds in solution seen by high resolution NMR and the 
resulting peak overlap may hamper proper identification. Assignments can be 
made more rigorously using extraction and in vitro high resolution NMR. One 
approach is to use MRS as a means of identifying the presence of particular 
molecules within a sample. Changes in the position and intensity of the spectral 
lines of these compounds can be interpreted in terms of metabolic or physiologic 
changes taking place within the sample. Presently human MR spectra can be 
obtained in vivo at a field strength of 1.5 T by field gradient based localisation 
and/or by use of surface coils which localise the signal to a volume immediately 
below the coil.
The relative intensities of the signals within a spectrum are proportional to the 
number of nuclei that give rise to them. Therefore, (relative) levels of molecules
19
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within a sample can be determined from the intensities of their respective signals 
under controlled circumstances.
One of the main advantages of MR for metabolic studies is that metabolic fluxes 
can be followed non-invasively, simply by monitoring how the signal areas of the 
compounds involved, vary with time.
ppm 5 0
Fig. 1 -3. 19F-spectrum of cell culture (cell suspension) treated with 5-FU; 1, FNuct; 2, 
FNucs; 3, 5-FU.
20
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MRS applications of various nuclei are:
(a) H MR: The proton is the most sensitive nucleus. The proton signals from 
water are exploited in MRI, whereas the proton signals from other compounds 
are used for metabolic studies.
31(b) P MR: The nucleus that has been used most extensively for metabolic
31studies is phosphorus-31. The dominant signals in P MR spectra of tissue such 
as brain and muscle include those of ATP, phosphocreatine (PCr), and inorganic 
phosphate (Pi), metabolites that have central roles in tissue energetics.
13(c) C MR: Carbon-13 has a natural abundance of only 1.1 per cent. Therefore, 
often isotopic enrichment is used to enhance sensitivity in labelling studies. 
The utilization of this technique is explored in human physiology and 
pathology related to glycogenesis [11].
19(d) F MR: Fluorine-19 is an excelent MR nucleus. Its intrinsic sensitivity is high,
1
0.83 compared to that of H. There are no endogenous compounds that give
19detectable background signals. The F nucleus is known to have a broad 
chemical shift range of about 500 ppm, reducing the changes of peak 
overlap.
(e) There are applications for other nuclei (including 14N, 15N, 23Na, and 39K) in 
the study of living systems.
19F MRS in tumour metabolism
In patient treatment we want to know in an early phase whether a tumour is 
responding to treatment. The main parameter is alteration in tumour size, mostly
19measured by imaging techniques. By F MRS it is possible to detect the
19presence of F containing anticancer drugs themselves in tumours and to follow
19their metabolism [12] and, thus, F MRS is a possible method for the early 
detection of reponse.
21
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19One of the in vivo pharmacokinetic applications of F MRS in animals [13] and 
humans [14] involves monitoring the metabolism of 5-FU. The hypothesis is that 
the amount of 5-FU, the formation of active anabolites and the formation of 
catabolites can be used to predict 5-FU activity against an individual tumour [15]. 
The main requirement is that drugs and metabolites should be present at a 
minimal tissue concentration of 10-6 M for studies in biological fluids or tissue 
extracts or of 10-4 M for in vivo studies [2,8].
Positron emission tomography (PET), another technique with considerable 
potential for monitoring the tissue distribution of drugs, can provide more 
sensitive detection of the positron emitting 18F isotope when administered as a 
component of 5-FU. However, in contrast to 19F MRS, 18F PET cannot separate 
5-FU from its metabolites.
5-FU cytotoxicity is mediated by conversion in the tumour to the FNuct which 
include FUTP, FdUTP and FdUMP. FUTP is incorporated into RNA, instead of 
UTP, yielding fraudulent RNA. To a lesser extent, FdUTP is incorporated into 
DNA. However, more important is the inhibition by FdUMP of the key enzyme of 
the pyrimidine de novo synthesis, thymidylate synthase (TS). This enzyme 
catalyses the conversion of dUMP to dTMP, and its inhibition results in decreased 
DNA synthesis. Detoxification (catabolism) of 5-FU is thought to occur 
predominantly in the liver. It is metabolised via DHFU and FUPA, leading to
19FBAL and fluoride anions (F-), which can be followed by F MRS. Selectivity for 
tumour over host tissue depends upon two principles: firstly the activities of the 
anabolic enzymes are raised (3-6-fold) in tumours; secondly the activity of the 
catabolic enzyme dihydrouracil dehydrogenase is very high in the liver [16]. 
Raised concentrations of FUTP, which can be formed intracellular at 
concentrations greater than 50 nmoles/g, would correlate with increased 
cytotoxicity [16]. However, the level of FdUMP does not always correlate with 
cytotoxicity [1]. A true indicator of a cell’s sensitivity to FdUMP might be the 
concentration of the ternary complex of FdUMP, the enzyme TS and the cofactor 
W5,W10-methylenetetrahydrofolate (derived from leucovorin), but its immobility and
22
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low concentration make detection by MRS in vivo difficult. Another important 
factor for 5-FU cytotoxicity could be the metabolic flux of fluorouracil elements, 
such as FdUMP, through the ternary TS complex.
19Many F MRS studies are performed in subcutaneously transplanted tumours in 
animals [17]. However, a problem common to transplanted tumours is that their 
blood supply is even more abnormal and chaotic than that in spontaneously 
occurring primary (or secondary) tumours. Several MRS studies on drugs that 
alter tumour blood flow have found effects in transplanted tumours that could not 
be reproduced in primary tumours. In addition, in experiments tumours are often 
grown to unreasonable large sizes relative to the host. This can perturb blood 
supply and give irrelevant data for the human situation.
Experimental approaches to study the working mechanism of 5- 
FU by 19F MRS
19The metabolism of 5-FU has been studied by 19F MRS in different tumour 
models [16]. Cell cultures and extracts of tumours have been used for this 
purpose as an in vitro approach [18-20]. The advantage of in vitro studies, which 
make use of high resolution NMR spectroscopy, is the high sensitivity reflected 
in a high signal-to-noise ratio. As longitudinal studies are not possible with in
19vitro F MRS, it is cumbersome to obtain pharmacokinetic data. Such studies
19are possible by in vivo F MRS of animals and humans [21,22]. In vivo studies 
of animals can give insight in 5-FU uptake, retention and metabolism and its 
effect on tumour growth. At first sight in vivo studies of patients seem most 
relevant, but this approach has also the most practical limitations. The sensitivity 
is lower than in animal studies and the limits within which one can vary 5-FU 
dose schedules are stricter.
Thus, several approaches can be used in a complementary way to study certain
19aspects of 5-FU behaviour. The goal of all F MRS studies is to perform
23
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preclinical and clinical studies in order to develop new treatment modalities for 
patient use. In the following part we will give an overview of this field.
19Current status of F MRS as applied to (colorectal) cancer and 
its potential in measuring 5-FU metabolism
19In vitro F MRS studies in cell lines
Keniry and colleagues [19] analysed extracts of murine and human tumour cell
19lines exposed to 5-FU with F MRS. They were able to detect 5-FU and FNuct, but 
no catabolites.
In extracts of Ehrlich ascites tumour cell lines incubated with 5-FU two peaks were
19observed with F MRS, representing 5-FU and the FNuct as a whole, respectively 
[23]. These findings correlated with growth inhibition studies in vitro. It appeared
19that F MRS visible levels of FNuct were predictive for the cytotoxicity of 5-FU.
19Thus, altogether in vitro F MRS studies in cell lines performed sofar enable 
visualisation of 5-FU and its anabolites, but not of its catabolites
19In vitro and in vivo F MRS studies in animal models
In 1984 Stevens and colleagues investigated the metabolism of 5-FU in implanted
19Lewis lung carcinomas and liver of C57Bl/6 mice by in vivo F MRS using surface 
coils [13]. In normal liver two catabolite peaks, FUPA and FBAL, were detected 
after a low dose of 5-FU and after a higher dose also a 5-FU signal was observed. 
In the tumour a 5-FU and one FNuct peak was seen, although at the low dose of 5- 
FU the latter signal was barely detectable.
19In vivo F MRS has also been performed on the rat Walker carcinosarcoma after 
5-FU administration. Peaks were identified as 5-FU and FNuct (one peak). In this 
study the dose of 5-FU, the level of FNuct and tumour growth inhibition appeared to 
correlate with each other [20]. Modulation by methotrexate (MTX) has also been 
tested in vivo. MTX pre-treatment of rats did increase the rate of FNuct formation
24
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19and the final amount formed as assessed by F MRS [24]. This correlated with 
improved growth inhibition. Similar results were found in colon carcinoma 
xenografts [25].
Using the CD8F1 murine mammary tumour in vivo, signals from 5-FU, FNuct, 
FBAL and FUPA were observed after 5-FU administration [26]. Formation of FNuct 
was increased with MTX pre-treatment.
5-FU treated RIF-1 tumours showed a positive correlation between the level of 
FNuct and the decrease in tumour volume [27]. The level of FBAL, the non-toxic 
end product of 5-FU inactivation, in the tumour did not correlate with tumour 
response.
Tumour extracts of the above-mentioned Walker carcinosarcoma were also
19measured with F MRS in vitro [20]. Apart from 5-FU and one FNuct peak, FBAL 
could be measured. HPLC quantitative analysis demonstrated that 50% of the 
FNuct consisted of the cytotoxic nucleotide FUTP that was increased three-fold in 
MTX pre-treated animals.
It is difficult to identify the different nucleotides, because of peak overlap. Lutz and 
Hull made assignments of the nucleotides of tumour extracts [28]. They suggested 
that a major signal contained mainly FUTP, whereas we thought it to be FdUMP. In 
another study they investigated the influence of dose, infusion route and time on 
the anticancer efficacy of 5-FU using a rat model [29]. The 5-FU dose (15, 30 or 60 
mg/kg), the infusion route (intra-arterial or intravenous) and the duration of the
19administration (bolus, 1 h, 5 h or 24 h) were varied. F MRS ex vivo was performed 
of tumour, liver and kidney by suspending several small pieces of tissue. The best 
response with lowest toxicity was achieved via 5 or 24 h intra-arterial infusion and 
correlated with the most favourable ratio of FNuct in tumour versus liver.
19F MRS studies of modulator effects on 5-FU metabolism have also been carried 
out in vivo in animals or humans, including for example MTX [24], a-interferon (a- 
IFN) [30], leucovorin (LV) [31], thymidine [13], and allopurinol [20]. An increased 
FNuct peak was visible after concurrent treatment with MTX, a-IFN and thymidine, 
whereas allopurinol suppressed FNuct formation.
25
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19In vitro and in vivo F MRS studies in human tissue
Using excised tissue samples from patients with liver metastases from colon 
carcinoma who had received 5-FU chemotherapy, 5-FU and its catabolites and 
anabolites could be measured in normal liver as well as in metastases [32].
Wolf and Presant and colleagues considered trapping of 5-FU in tumour or 
metastasis a good prognostic factor for response to therapy [21,33]. Trapping was 
defined as a half-life of 5-FU in tumours much longer (20 minutes or more) 
compared to the half-life of 5-FU in blood (8-12 minutes). Free 5-FU was detected 
in several tumours of patients with different types of cancer. No other metabolites 
were demonstrated in these tumours. In this study the extent of trapping of free 5- 
FU in tumours correlated with the antitumour response.
19In a pilot study by Findlay and colleagues [30] F MRS was used to monitor non- 
invasively the metabolism of 5-FU in liver metastases of colorectal cancer patients. 
The patients were treated with a continuous low-dose intravenous infusion of 5-FU 
until progression of the disease, at which time a-IFN was added, in order to 
modulate 5-FU activity favourable. Patients with a detectable 5-FU signal observed 
in the first 8 weeks of treatment were likely to respond to 5-FU treatment. At the 
time of a-IFN addition, some patients developed increased 5-FU signals, and some 
showed a signal from the active metabolites of 5-FU. In both cases there was a 
correlation with response to combined treatment with 5-FU and a-IFN.
Schlemmer and colleagues [34] found a correlation between 5-FU levels and
19volumes of metastases in the liver region within the field of view of the F MR coil. 
5-FU levels in patients at their initial 5-FU chemotherapy were related with clinical 
response determined after 3 cycles of treatment. Responders had enhanced 5-FU 
levels compared with non-responders. In addition, it was possible in this study to
19monitor FBAL kinetics. The same group also performed F MRS on cervical lymph 
node metastases of patients with head and neck carcinoma [35]. Patients were 
treated with simultaneous radiotherapy and chemotherapy, containing 5-FU. 
Resonances of 5-FU, DHFU and FBAL were resolved. 5-FU and FBAL levels were
26
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higher at the second chemotherapy cycle compared with the first examination. No
19correlation of clinical response and F MRS parameters was found.
19Li and colleagues [36] obtained MR imaging-directed F MR spectra localized 
using three-dimensional chemical shift imaging (3D CSI). They studied the liver of 
patients receiving 5-FU. The concentration of FBAL in liver was determined.
Outline of the thesis
The objective of the thesis is to investigate the effect of 5-FU at the site of the 
colorectal tumour (pharmacodynamics) and the influence of the tumour 
vascularisation and perfusion on the activity of 5-FU. The main techniques used are
19F magnetic resonance spectroscopy (MRS) and dynamic contrast-enhanced
19MR imaging (dMRI). F MRS can give us information about the behaviour of 5-FU 
in situ in the tumour in animals and in liver metastases in patients. This can learn us 
how the effect of treatment with 5-FU is established and it gives us the opportunity 
to study the effect of modulators on the metabolism of 5-FU. dMRI is a technique 
which shows aspects of the vascularisation of the metastases. This information will 
be correlated with response to treatment.
19In chapter 1 an introduction to MR is given. Especially F MRS of the 5-FU 
metabolism in colorectal cancer is discussed.
In chapter 2 a review is given of 5-FU therapy in the treatment of colorectal cancer. 
Described are rationale and clinical results of frequently used treatment schedules 
including drugs used for modulation of 5-FU efficiency.
19To study the metabolism of 5-FU, we performed a F MRS study in vitro of tumour 
extracts (chapter 3). In this chapter the effect of modulators on 5-FU metabolite 
patterns in the murine C38 colon carcinoma have been described.
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Because a substantial part of the tumours described in chapter 3 consisted of
19necrosis, we performed a second F MRS study in vitro of tumour extracts 
(chapter 4). In this chapter the data of the 5-FU metabolite patterns in viable and 
necrotic tumour areas of murine colon carcinoma are reported.
To study the pharmacokinetics of 5-FU and the role of vascularisation and
19perfusion in vivo, we performed a F MRS study in mice (chapter 5). Carbogen 
breathing can influence tumour uptake of 5-FU by changes in tumour blood flow.
In this chapter the effect of carbogen on the 5-FU metabolism in the murine C38 
colon carcinoma is given.
19Subsequently, another in vivo F MRS study in mice (chapter 6) was performed to 
compare treatment response to 5-FU of two different variants of the murine C26 
colon carcinoma, with a different sensitivity to 5-FU.
We hypothesised that MRS and MRI parameters could correlate with response to 
treatment. To investigate this, a clinical study was initiated, in which patients with
19liver metastases of colorectal cancer, treated with 5-FU, were studied by F MRS 
and dMRI of the liver (chapter 7).
In chapter 8 the results are summarised and discussed.
28
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Abstract
Colorectal cancer is one of the most frequent cancers in the western world. 
Approximately half of the patients will die of their disease because of metastases. 
The most active cytotoxic agent used to date is 5-fluorouracil (5-FU). However, 
clinical responses are achieved only in a minority of patients. Based on the current 
knowledge of the mechanism of action of 5-FU, many attempts have been made to 
improve the clinical results. These include the use of biochemical modulators and 
different methods of administration, and these are the subject of this review. 
Specifically, of five different modulators, i.e. leucovorin, methotrexate, interferon-a, 
N-(phosphonacetyl)-L-aspartate and trimetrexate glucuronate, the biochemical 
background and the clinical results obtained with these modulators are discussed. 
In order to get more insight, an overview of the 5-FU metabolism has been given. In 
addition, the different methods of systemic administration of 5-FU as well as 
possible mechanisms underlying 5-FU resistance are described.
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Introduction
The prognosis of metastatic colorectal cancer is dismal. The median survival of 
advanced colorectal cancer is approximately 6 months for untreated patients. Since 
its synthesis in 1957 by Heidelberger, 5-fluorouracil (5-FU) is still the most effective 
drug in metastatic disease [1]. Response percentage of 5-FU containing regimens 
varies between 10 and 30%. The response rate has been improved in recent 
decades by the use of various biochemical modulators. However, the question 
remains if this may be ascribed to improvement of the modulation, because in most 
randomized studies modulated 5-FU was not compared with equitoxic doses of 
unmodulated 5-FU. The modulators that are discussed in this review are leucovorin 
(LV), methotrexate (MTX), interferon (IFN)-a, N-(phosphonacetyl)-L-aspartate 
(PALA) and trimetrexate glucuronate (TMTX) (Fig. 2-1). The modulators have been 
used in clinical trials during the past decade. Recently developed modulators with 
promising activity are mentioned briefly. Preclinical research has also resulted in 
the exploration of different methods of 5-FU administration. We will discuss bolus 
injection, continuous infusion and chronomodulation. Information on possible 
mechanisms underlying 5-FU resistance is reviewed.
Mechanism of action of 5-FU
5-FU is metabolized into active anabolites, in particular in tumor cells, and into 
inactive catabolites, especially in the liver, but also in extrahepatic tissue [2-4]. 5-FU 
itself is rapidly cleared from the plasma within 15-20 min, but its metabolites may 
persist in the tissues for several days [5].
The scheme of 5-FU metabolism is presented in Fig. 2-1. Only a small percentage 
(1-3%) of the total body dose of 5-FU is converted to the therapeutically relevant 
anabolites: the fluoronucleosides (FNucs) and fluoronucleotides (FNuct) [6].
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Fig. 2-1. Diagram of the interaction between 5-FU and pyrimidine metabolism. Modulators 
are printed bold, enzymes in italics; solid arrows, stimulation; dashed arrows, inhibition; ATC, 
aspartate transcarbamylase; OPRTase, orotate phosphoribosyltransferase; TP, thymidine 
phosphorylase; TK, thymidine kinase; DPD, dihydropyrimidine dehydrogenase; DHFR, 
dihydrofolate reductase. The ternary complex responsible for TS inhibition is represented by 
a circle. Abbreviations other then used in the manuscript; CHOTHF, CHO-tetrahydrofolate, 
CP, carbamyl phosphate; CA, carbamyl aspartate; OA, orotic acid; TdR, thymidine; F-, 
unknown fluor combinations.
The most important FNuct for the cytotoxic effect of 5-FU are 5-fluoro-2'-deoxyuridi- 
ne-5'-monophosphate (FdUMP) and 5-fluorouridine-5'-triphosphate (FUTP), the 
latter generally occuring at a much higher concentration [7]. Initial steps in the 
anabolic metabolic pathways of 5-FU are its conversion to the FNucs 5-fluorouridi- 
ne (FUrd) and 5-fluoro-2'-deoxyuridine (FdUrd), and to 5-fluorouridine-5'-monop- 
hosphate (FUMP). The latter can be constituted from FUrd, but is mainly formed
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directly via the orotate phosphoribosyltransferase (OPRTase) enzymatic system in 
the presence of the co-substrate 5-phosphoribosyl-pyrophosphate (PRPP). FUMP 
is further converted either to FUDP and then to FUTP via a kinase system, or 
FUDP is converted to FdUDP via the ribonucleotide reductase enzymatic system, 
and then to the mono- and triphosphate derivates (FdUMP and FdUTP) [8]. A large 
fraction (80-85%) of the administered 5-FU is degraded to catabolites, i.e. 5',6'- 
dihydro-5-fluorouracil (DHFU), a-fluoro-G-ureidopropionic acid (FUPA) and a- 
fluoro-R-alanine (FBAL) [2,6]. Between 5 and 20% of 5-FU is excreted unchanged 
in the urine.
Three major mechanisms underlying the antitumor activity of the FNuct have been 
suggested and the relevance of these mechanisms is still a matter of considerable 
debate [1,9]. First, inhibition by FdUMP of the key enzyme of pyrimidine de novo 
synthesis, thymidylate synthase (TS). This enzyme catalyses the conversion of 
dUMP to dTMP and its inhibition results in decreased DNA synthesis. Second, 
incorporation of FUTP into RNA, yielding fraudulent RNA. Third, incorporation of 
FdUTP into DNA [8]. However, the extent to which the last mentioned 5-FU 
incorporation into DNA relates to 5-FU cytotoxicity is unclear. It is generally agreed 
upon that the FNuct formed as a result of anabolism are responsible for the thera­
peutic effect of 5-FU.
Catabolism of 5-FU to FUPA and FBAL in normal tissues is a detoxification mecha­
nism.
In order to increase the ratio of anabolism to catabolism, biochemical modulators 
have been used. Biochemical modulation involves the use of one or more agents, 
which themselves may be devoid of cytotoxic activity, but which enhance the antitu­
mor effect or the selectivity of an active antitumor drug by altering the biochemical 
pathways involved [10]. Ideally the effect of the modulators on 5-FU metabolism 
should be more pronounced in tumor tissue than in normal tissues, but 
unfortunately this is not the case. For 5-FU, several modulators of its antitumor 
activity have been reported, although the actual effect of the different modulators
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on 5-FU metabolism has not been unambiguously demonstrated for all of these 
modulators [11].
Biochemical modulators of 5-FU
Multiple factors are associated with the sensitivity of tumor cells to 5-FU. These 
include the presence of co-substrates (e.g. PRPP), the activity of anabolic enzymes 
(e.g. OPRTase), the presence of competing nucleosides (e.g. uridine) and nucle­
otides (e.g. deoxythymidine triphosphate [dTTP]), the kinetics of the catabolism of 
5-FU, the extent of conversion of 5-FU into FUMP and FdUMP, and alterations in 
the amount of TS present (e.g. gene amplification) [12]. Biochemical modulation of 
5-FU activity may be accomplished by interfering with each of these determinants 
in order to improve the therapeutic index. This concept has been most extensively 
tested in the treatment of human colorectal cancer [3,9,11].
Specific exposure protocols might be required for the in vivo biochemical 
modulation of 5-FU activity. Thus, differences in the sequence and time schedule of 
administration of the two agents (5-FU and its modulator) may contribute to the 
different results of clinical trials.
LV
LV increases the stability of the FdUMP-TS-W5,W10-methylenetetrahydrofolate 
ternary complex. This ternary complex is formed because FdUMP, one of the 
metabolites of 5-FU, binds to TS in the presence of W5,W10-methylenetetrahydro- 
folate (CH2THF). This interaction leads to the formation of a covalent ternary 
complex and to the inhibition of TS. Thus FdUMP acts as a suicide inhibitor for TS, 
forming a covalent ternary complex with the enzyme in combination with the cofac­
tor CH2THF [11,13]. The degree of inhibition of TS and the persistence of this 
inhibition are essential factors for maximal growth inhibition by 5-FU [9]. 
Administration of 5-FU together with LV results in an increase in the intracellular
38
5-Fluorouracil in colorectal cancer
concentration of CH2THF and in stabilization of the ternary complex [14]. As a 
consequence, the essential nucleotides for the synthesis of DNA (dTTP) are deple­
ted, eventually resulting in cell death [2,15]. In addition to this role in TS inhibition, 
FdUMP can be converted to FdUTP and incorporated into DNA, resulting in strand 
breaks [16].
MTX
MTX causes an increase of the intracellular pool of PRPP through inhibition of the 
de novo purine synthesis. The increased PRPP concentration results in increased 
conversion of 5-FU to FUMP by OPRTase, which uses PRPP as a co-substrate. 
Increased formation of FUMP results in an increased formation of FUTP with 
increased probability of the incorporation of FUTP instead of UTP into RNA, 
causing cytotoxicity [2,17]. Moreover, MTX is a potent competitive inhibitor of 
dihydrofolate reductase (DHFR). This enzyme is required for the regeneration of 
tetrahydrofolate (THF), which is essential for the synthesis of dTMP [13]. Inhibition 
of dTMP synthesis adversely affects DNA synthesis.
IFN-a
IFNs induce changes in the pharmacokinetics of 5-FU. However, the exact mecha­
nism of the interaction between IFN-a and 5-FU is still unknown. IFN-a is reported 
to reduce the plasma clearance of 5-FU and to enhance the incorporation of 5-FU 
into RNA [18,19]. IFN-a has been found to increase the expression of the enzyme 
thymidine phosphorylase (TP), which catalyzes the first step in the conversion of 5- 
FU to the active metabolite FdUMP in human colon carcinoma cells [19,20]. The 
formation of FdUMP plays a central role in 5-FU therapy through inhibition of TS as 
described above [21]. It has also been observed that IFNs reduce cellular uptake of 
thymidine and reduce the activity of the enzyme thymidine kinase (TK). In this way 
the normal biochemical role of thymidine in nucleic acid synthesis, necessary for 
cell replication, is disrupted.
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PALA
PALA has been reported to inhibit aspartate transcarbamylase (ATC), a key 
enzyme of the de novo pyrimidine biosynthesis, by competing with its natural 
substrate, carbamyl phosphate [9,22]. This leads to an increase in PRPP, a deple­
tion of orotic acid (the precursor of UMP), and the depletion of uracil and cytosine 
nucleotides (UMP, UDP, UTP and CTP) and pyrimidine deoxyribonucleotides 
(dUMP, dUTP and dTTP) [11]. A decreased dUMP concentration causes 
decreased competition with FdUMP for TS binding. The increased availability of 
PRPP can be expected to favor the formation of FUMP via OPRTase as already 
outlined above [2,22-25].
TMTX
TMTX is a non-classical quinazoline antifol that lacks a terminal glutamic acid 
residue. Like MTX, TMTX competitively inhibits dihydrofolate reductase and 
increases intracellular concentrations of PRPP [26,27]. Unlike MTX, TMTX is 
lipophilic and appears to enter cells by passive diffusion. It does not undergo 
intracellular polyglutamation and it does not require the reduced folate transport 
system, and therefore does not compete with LV for cellular uptake and 
metabolism [28,29].
19F NMR
19To study the effectivity of a combination of 5-FU with a modulator we use F NMR 
spectroscopy. With this method it is possible to detect 5-FU and its metabolites in
19fluids and in living tissues. We use F spectroscopy to investigate the 5-FU 
metabolism in vitro and in vivo in rodents and recently also in vivo in patients with 
advanced colorectal cancer receiving 5-FU treatment. In our study of tumor extracts
19of murine colon tumors treated with 5-FU and different modulators studied with F 
NMR spectroscopy in vitro, we concluded PALA was not effective as was later 
approved by the clinical study [30].
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Methods of 5-FU administration
5-FU is usually administerd as a bolus, i.e. short term infusion. The importance of 
administering 5-FU in bolus schedules, indeed as short-term infusions, is illustrated 
by the following studies. In a retrospective non-randomized study patients receiving 
a 5-FU bolus injection within two min had a higher response rate compared to 
patients receiving the same 5-FU dose in 20 min; 32 versus 10%, respectively (P <
0.001). In spite of more toxic side effects, more subjective improvement was noted 
in the former group of patients [31]. In a prospective randomized trial bolus 5-FU 
administration, given as an injection during 2-4 min, was compared with short-term 
infusion lasting for 10-20 min; both combined with LV [32]. In the first group 27% 
responses were seen versus 13% in the second group (P = 0.02), whereas both 
groups showed no difference in toxicity and long-term survival.
Because 5-FU is an antimetabolite and therefore only active in dividing cells and 
because colorectal cancer is a slowly growing tumor, a longer exposure time 
should result in the uptake of 5-FU by more tumor cells. With continuous infusion a 
higher dose intensity can be reached. In continuous infusion schedules 5-FU is 
usually infused over 24 or 48 h or protracted for several weeks. Bolus injections 
and continuous infusion are thought to have different mechanisms of cytotoxicity 
and of resistance. Administration of 5-FU as a bolus injection produces high plasma 
levels of 5-FU and increased FUTP incorporation into RNA, whereas continuous 
infusion results in low plasma levels of 5-FU and lower RNA incorporation but 
prolonged TS inhibition [33]. Partial response and disease stabilization have been 
obtained with continuous infusion in patients who were in progression after bolus 
treatment, supporting the experimental finding that resistance to bolus 5-FU may be 
overcome by continuous infusion 5-FU [34]. Bolus injections and continuous 
infusion have been alternated in order to overcome resistance [35].
Although continuous infusion generally increases the response rate compared with 
bolus injections, there is no big difference in overall survival [36]. However, there is 
a different toxicity pattern with stomatitis being more severe after continuous
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infusion and leucopenia after bolus injection [37,38]. A popular regimen is the 
combination of bolus injection and continuous infusion [39]. In a randomized trial 
this regimen was superior to monthly low-dose LV and 5-FU bolus in terms of 
response rate and toxicity, but not in survival. In a meta-analysis, which involved six 
randomized trials of continuous infusion 5-FU versus bolus 5-FU, a significantly 
higher response rate (22 versus 14%, respectively) and median survival (12.1 
versus 11.3 months, respectively) was demonstrated in favor of continuous infusion 
5-FU, although the median survival times were close [36].
Circadian timing of drug delivery (chronomodulation) is a method to further improve 
dose intensity compared with protracted infusion at a flat rate. This is based on 
observations on circadian changes in the enzymatic activities involved in 5-FU 
catabolism and anabolism as well as in the proliferative activity of target tissues of 
toxicity (i.e. bone marrow and mucosa). Programmable-in-time pumps allow to test 
the clinical relevance of this principle.
Mechanisms underlying 5-FU resistance
As is pointed out in the Introduction, response rates to 5-FU treatment in advanced 
colorectal cancer vary between 10 and 30%. Virtually all patients eventually 
develop resistance to 5-FU. Three possible mechanisms of resistance have been 
observed and will be described here.
The first mechanism underlying 5-FU resistance occurs at the level of TS inhibition. 
The relevance of both pre- and post-treatment TS activity or expression has been 
demonstrated. As to pre-treatment TS activity, intratumoral ratios of TS/G actin 
mRNA for tumor biopsies of disseminated colorectal cancer patients have been 
determined and the median TS/G actin ratio was found to significantly segregate 
responders (low ratio) from non-responders (high ratio) [40]. Also median survival 
was longer for patients with a low ratio. Furthermore, intratumoral TS levels were 
correlated with overall survival [41]. The importance of the post-treatment 5-FU-
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induced increase of TS and of the duration of TS inhibition has been demonstrated. 
High TS levels and low inhibition of TS upon 5-FU exposure correlated with no 
response to 5-FU in colorectal cancer patients [42]. Evidence has accumulated that 
insufficient inhibition of TS by FdUMP may be a major resistance mechanism [43]. 
The second mechanism suggested to underly 5-FU resistance is related to the 
activity of folylpolyglutamate synthase (FPGS), the enzyme responsible for folate 
polyglutamation. As described above, LV acts as a precursor for CH2THF, which 
supports the formation of the ternary complex between TS, CH2THF and FdUMP 
resulting in irreversible TS inhibition. Reduced folates inside the cells are present 
as polyglutamated forms of CH2THF and exhibit an increased affinity for TS as 
compared to the non-polyglutamated form. Furthermore, polyglutamation increases 
the intracellular retention of reduced folates. Thus, polyglutamates of CH2THF 
achieve an even better inhibition than CH2THF itself [44]. A decreased activity of 
FPGS has been associated with resistance to 5-FU [45]. The determination of 
FPGS activity may therefore be a promising tool for identifying 5-FU/LV-responsive 
tumors.
A third mechanism possibly involved in 5-FU resistance is the enzyme dihydropyri­
midine dehydrogenase (DPD). DPD activity is high in normal liver and variable in 
tumors [46]. DPD is the first and rate-limiting enzyme of 5-FU catabolism [47]. 
Since a high rate of 5-FU catabolism may be one of the reasons of 5-FU resistance 
and high DPD activity results in a high rate of catabolism, DPD activity in tumor 
cells is a factor significantly related to 5-FU sensitivity [48]. Intratumoral DPD of 
complete responders has been compared with partial or non-responders in head 
and neck cancer patients treated with 5-FU and a trend towards significantly lower 
activity of tumoral DPD in the complete responders was found [47].
43
Chapter 2
Clinical results
Biochemical modulation of 5-FU bolus infusion
The most extensive clinical data have been obtained for three modulators, namely 
LV, MTX and IFN-a. PALA has been investigated to a lesser extent. TMTX is a 
new and promising modulator in preclinical and early clinical studies. The 
combination of modulators is still experimental.
In the following paragraphs we will discuss clinical studies in metastatic colorectal 
cancer with the above mentioned modulators. Combination therapies of 5-FU with 
a modulator are compared to therapy with 5-FU alone.
5-FU and LV
The results of phase II trials suggest that the combination of 5-FU and LV 
enhances the activity of 5-FU in patients with advanced colorectal cancer [49]. A 
substantial number of large randomized phase II and III studies shows improved 
response rates for 5-FU when dosed in combination with LV [21].
In 1992 a meta-analysis on nine randomized clinical trials showed a significant 
benefit of 5-FU plus LV over 5-FU alone in terms of response rate (23 versus 11%, 
respectively). However, no significant improvement of overall survival was found 
(11.5 versus 11.0 months, respectively) [50].
High-dose LV did not appear to be superior to low-dose LV [50-52].
Although weekly and monthly schedules differ in toxicity, with more diarrhea for the 
weekly regimen and more mucositis for the monthly regimen, no difference in 
response rate and survival was shown between these schedules [52].
A caveat in most randomized studies is that 5-FU has been given at equal doses 
both with and without modulation, resulting in a suboptimal 5-FU dose in the control 
arm, which was also suggested in the meta-analysis. When 5-FU/LV was 
compared with equitoxic doses of 5-FU, no difference in treatment outcome was 
found [53]. The mean 5-FU dose was significantly higher in the 5-FU group (472 
versus 420 mg/m2/week, P = 0.0003).
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5-FU and MTX
The results of phase II trials suggested an increased response rate on account of 
MTX modulation from 10-20 to approximately 30% [54]. Subsequent phase III trials 
yielded equivocal results [12,21]. A meta-analysis showed that MTX has a small 
but significant advantage over 5-FU alone in terms of response rate (19 versus 
10%; P < 10-4) and survival (10.7 versus 9.1 months, P = 0.024) [55].
The dose of MTX, and the interval between MTX and 5-FU administration have 
been mentioned as relevant factors [21]. However, in the meta-analysis these 
factors did not appear to have an impact [55].
There is a possibility that LV, given as rescue after high-dose MTX, may also act as 
a biomodulator and may therefore obscure the modulating role of MTX in these 
schedules.
After 1992 5-FU/MTX has mainly been compared to 5-FU/LV and not to 5-FU 
alone. Several authors found no difference in therapeutic activity between these 
treatment combinations and in one study 5-FU/MTX was more toxic [56-58]. In one 
study an enhanced response rate was demonstrated for 5-FU/MTX with increased 
toxicity compared to 5-FU/LV given suboptimal [59].
5-FU and IFN-a
Based on promising results of the combination of 5-FU and IFN-a in phase II 
studies, this combination was tested in randomized trials [60]. In these phase III 
studies no beneficial effect of 5-FU/IFN-a as compared to 5-FU alone or to 5-FU 
plus LV was demonstrated [61]. Since the combination of 5-FU with IFN-a is 
associated with a higher toxicity compared to other 5-FU regimens, currently there 
appears to be no role for this combination.
In 2001 two meta-analyses were published, concluding that IFN-a does not 
increase the efficacy of 5-FU or of 5-FU + LV, and that 5-FU + IFN-a is 
significantly inferior to 5-FU + LV, for patients with advanced colorectal cancer 
[62].
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5-FU and PALA
Many clinical trials of 5-FU and PALA have shown disappointing results. This is 
probably due to inefficient doses of 5-FU and PALA [3,12,63]. At high doses of 
PALA, toxic effects become unacceptable. Phase II trials with low doses of PALA 
administered 24 h before the maximal tolerated dose of 5-FU yielded a response 
rate of 43% [23,64].
5-FU and TMTX
Since TMTX does not compete with LV and reduced folates for uptake and 
polyglutamation, synergistic modulation of 5-FU cytotoxicity may be achieved with 
the combination TMTX/5-FU/LV. A recent phase II trial of TMTX, LV and 5-FU 
revealed a 20% partial response rate in 35 previously treated patients [65] and a 
50% overall response rate in 30 previously untreated patients with colorectal 
cancer [66]. Based on these results two international randomized trials comparing 
5-FU modulated by LV with or without TMTX have started in 1996 until 1999 in 
Europe and in the USA. In 2001 the results of these trials are not published yet.
Double modulation of 5-FU
On theoretical grounds it may be interesting to combine 5-FU with more than one 
modulator. With this approach the metabolism of 5-FU may be influenced at 
different points. With the different mechanisms of action of the above-mentioned 
modulators in mind (Fig. 2-1), one could think of the use of several combinations, 
e.g. one modulator enhancing TS inhibition and the other increasing incorporation 
of FUTP into RNA, or two modulators enhancing TS inhibition at a different point.
5-FU and MTX with or without PALA
In the study of 5-FU and MTX with or without PALA, double modulation was not 
effective [67].
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5-FU and PALA and LV
In another phase II study 5-FU was combined with PALA and LV, and yielded a 
response rate of only 6.1% [68].
5-FU and MTX and LV
As already mentioned, LV has to be given 24 h after high-dose MTX as a rescue to 
protect the normal tissues for toxicity. This time interval of 24 h is important. 
Increased response rates with no difference in median survival and enhanced 
toxicity has been observed with this double modulation [58,59].
5-FU and LV and IFN-a
The addition of IFN-a to 5-FU and LV did not improve response rates, but was 
found to be more toxic [62,69].
Other combinations
Several other combinations of modulators with 5-FU have been applied. 5-FU 
modulated by MTX and IFN-a had a low response rate and resulted in severe 
toxicity [70]. Furthermore, other modulators have been added to modulation with 
LV, MTX or IFN-a. For example, 5-FU has been applied with LV and hydroxyurea 
and with LV and cisplatin [71,72]. Both combinations were well tolerated in these 
studies. High response rates were achieved without an apparent survival 
advantage.
Based on preliminary data the double modulation of 5-FU with TMTX and LV may 
be more promising [65,66].
Continuous 5-FU infusion
Flat rate infusion
Commonly, infusional 5-FU is administered at a flat rate [36].
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Chronomodulated infusion
One of the largest studies of chronomodulated chemotherapy was carried out by 
Levi et al. in colorectal cancer patients [73]. They compared chronotherapy with 
oxaliplatin, 5-FU, and LV with constant-rate infusion of these agents. Chrono­
therapy was more effective and less toxic than constant-rate infusion.
Biochemical modulation of infusional 5-FU
Effective biochemical modulation of infusional 5-FU has been demonstrated in only 
one randomized trial. In this trial the effect of MTX modulation was examined and a 
significant increase of the response rate from 10 to 21% (P = 0.025) was shown for 
modulated infusional 5-FU [74]. However, survival was not improved. Given the low 
toxicity which was shown in this trial, one could agree that 5-FU doses were 
suboptimal. The addition of PALA to this 5-FU/MTX regimen in a subsequent 
randomized trial was not shown beneficial [67]. In several phase II trials no 
apparent benefit was shown for the biochemical modulation of infusional 5-FU [75­
77].
Discussion
To date, 5-FU remains the backbone of therapy for advanced colorectal cancer. It 
is important to understand the mechanism of action of 5-FU in order to be able to 
influence treatment with this drug. To obtain optimal results with biochemical 
modulation, it is necessary to understand the biochemical background of the 
different modulators and their interaction with the metabolism of 5-FU. In order to 
improve the results of treatment, new modulators are under investigation in the
19preclinical and in the clinical setting. 19F NMR spectroscopy is a method to study 5- 
FU metabolism in a preclinical as well as in a clinical setting. Factors that are 
important for 5-FU sensitivity and resistance are the intracellular concentration of
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reduced folates, the extent of TS inhibition, and the activity of FPGS and DPD. Pre­
treatment TS values can be of predictive value for therapy outcome.
Using a variety of modulators, response rates of 5-FU regimens vary between 15 
and 30%. The only modulators that have shown efficacy in terms of response rate 
in randomized trials are LV and MTX. Despite this, the preferred regimen of 5-FU is 
still a matter of debate.
In spite of a theoretical advantage, to date the combination of several biochemical 
modulators has not been proven advantageous. In this respect the combination of 
TMTX with LV may be promising, but the result of randomized trials should be 
awaited.
With continuous infusion schedules higher dose intensities are achieved. 
Compared to bolus infusions, this has translated in higher response rates, a more 
favourable toxicity pattern and a small benefit in overall survival [36]. Possible 
draw-backs are the need for portable infusion pumps and implanted venous 
catheters. Data on quality of life and health-care economics for randomized trials 
are lacking.
Chronotherapy appears to be a way by which a further increase in dose intensity 
may be reached. To date, however, this approach has also not shown a survival 
benefit.72
There are several new chemotherapeutic agents nowadays which are evaluated for 
the treatment of colorectal cancer. These include direct TS inhibitors (raltitrexed), 
topoisomerase inhibitors (irinotecan or CPT-11) and a cisplatin analog, showing 
activity in colorectal cancer (oxaliplatin) [78-80]. Furthermore, oral 5-FU prodrugs 
such as capecitabine (doxifluridine or 5-dFUR) and UFT (ftorafur plus uracil) have 
promising activity and toxicity patterns [81,82]. In addition, ethynyluracil, an oral 
dihydropyrymidine dehydrogenase inhibitor, appeared to increase the plasma level 
of 5-FU and is in early clinical development [83].
In summary it can be concluded that improved understanding of the biochemical 
pharmacology of 5-FU has led to the development of several biochemical modula­
tion strategies which are currently being tested in clinical trials. A close collaborati­
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on between preclinical and clinical investigation is important in order to get the best 
results. Until now, 5-FU without modulator given at maximal tolerated dose has 
never been proven to be inferior to 5-FU plus modulator. In future studies it is 
important to use optimal and equitoxic doses of 5-FU, which was often not the case 
in the past. Only then can the efficacy of new modulators or infusion methods be 
compared to the currently used treatment.
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Abstract
19High-resolution F nuclear magnetic resonance spectroscopy at 7 T was used to 
study the effect of modulators on the metabolism of 5-fluorouracil (5-FU, 115 mg/kg
i.p.) in C38 murine colon tumors grown in C57Bl/6 mice. Distinct 5-FU metabolite 
patterns were found in perchloric acid extracts of these tumors after treatment.
19The F nuclear magnetic resonance spectra exhibited resonances representing 5- 
FU, the catabolites a-fluoro-G-ureidopropionic acid and a-fluoro-R-alanine, as well 
as four distinct fluoronucleotide anabolites. Using this model system the effect of 
several modulators on 5-FU tumor metabolite patterns was investigated: 
methotrexate (300 mg/kg); a-interferon (10 IU/animal); W-(phosphonacetyl)-L- 
aspartate (100 and 250 mg/kg); and leucovorin (300 and 750 mg/kg). A significant 
increase in the anabolite:catabolite ratio was observed for the groups treated with 
5-FU in combination with the modulators methotrexate (n = 8), a-interferon (n = 7), 
and high-dose leucovorin (n = 14), but not for low-dose leucovorin (n = 7). Cotreat­
ment with high-dose W-(phosphonacetyl)-L-aspartate (n = 8) resulted in a 
significant decrease in the anabolite:catabolite ratio compared to treatment with 5- 
FU alone (n = 16). Possible correlations of metabolite profiles with therapy 
response are discussed.
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Introduction
5-FU is the most important drug in the treatment of advanced colorectal carcinoma 
[1]. In the last decade, it was possible to increase the response to 5-FU from about 
20 to 30% by alterations in the mode of administration and the use of modulators 
[2-4]. 5-FU is metabolized into active anabolites, in particular in tumor cells, and 
into inactive catabolites, in particular in the liver, but also in extrahepatic tissue [5­
7]. This theory is supported by the fact that in colon tumor cell lines incubated with 
5-FU only anabolites are formed, but no catabolites. Fig. 3-1 presents a scheme of 
5-FU metabolism. Only a small percentage of the 5-FU is taken up in tumor cells 
and converted to the therapeutically important anabolites: the fluoronucleosides 
(FNucs) and fluoronucleotides (FNuct). The most important FNuct are 5-fluoro-2'- 
deoxyuridine 5'-monophosphate (FdUMP) and 5-fluorouridine 5'-triphosphate 
(FUTP), the latter generally occurring at a much higher concentration [8]. A large 
fraction of the administered 5-FU is degraded to catabolites of which 5,6-dihydro-5- 
fluorouracil (DHFU), a-fluoro-G-ureidopropionic acid (FUPA), and a-fluoro-R-alanine 
(FBAL) are the most important [5]. The precise mechanism underlying the 
antitumor activity of the FNuct is still a matter of considerable debate [1,4]. Incorpo­
ration of the FNuct into both RNA and DNA has been reported as possible 
pathways for antitumor activity. In vivo nuclear magnetic resonance (NMR) studies 
have actually correlated FNuct levels with therapeutic response [9-13]. Modulators 
have been used in order to increase the anabolism of 5-FU at the cost of its catabo­
lism. Biochemical modulation involves the use of agents, which themselves may be 
devoid of cytotoxic activity but which enhance the antitumor effect or the selectivity 
of an active antitumor drug by altering the biochemical pathways [14].
The main objective of the present study was to obtain more insight into the effects
19of modulators on 5-FU metabolite profiles in tumor tissue by using F NMR 
spectroscopy.
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Fig. 3-1. Interaction between 5-FU and pyrimidine metabolism. Modulators are shown in 
boxes; enzymes are shown in circles; +, stimulation; -, inhibition; +/-, LV and MTX stimulate 
(+) FdUMP-ChhTHF-TS complex formation resulting in inhibition (-) of the normal thymidylate 
synthase (TS) catalysis; 1, aspartate transcarbamylase (ATC); 2, orotate phosphoribo- 
syltransferase (OPRTase). The ternary complex responsible for TS inhibition is represented 
by a hexagona. CP, carbamyl phosphate; OA, orotic acid; CH2THF, W5,W10-methyle- 
netetrahydrofolate; PRPP, 5-phospho a-D-ribosyldiphosphate; F-, unknown fluor 
combinations.
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If changes in metabolism, i.e. enhanced anabolism, can be predicted, it may be 
possible to rationally design treatment protocols that are likely to have improved
19response rates. Although many F NMR studies on 5-FU metabolism have been 
done in vivo [9,10,15-17], we decided to perform an in vitro study, because of the 
improved resolution of individual metabolite signals and the significantly lower 
detection threshold. The modulators investigated in the present study were methot­
rexate (MTX), N-(phosphonacetyl)-L-aspartate (PALA), a-interferon (IFN), and 
leucovorin (LV). MTX and LV have already proved to be active in some patient 
studies [18,19]. IFN has also been used in patients to improve 5-FU treatment [20]. 
PALA is now used as a new modulator in phase II studies [21]. The biochemical 
effects of these modulators are schematically presented in Fig. 3-1. For details see 
Refs. 5 and 22-30.
Materials and Methods 
Tumor model
Female C57BL/6 mice of 8 to 12 weeks of age were obtained from the Central 
Animal Laboratory of our university. The C38 murine colon tumor, which is known 
to be sensitive to 5-FU, was acquired from Dr. P. Lelieveld of the REPGO-TNO 
Institute, Rijswijk, the Netherlands, and is described elsewhere [31]. Tumor tissue 
fragments with a diameter of 3 mm were implanted s.c. in the right flank of the 
mouse. Treatment was performed after 20 to 21 days, when the tumors reached a 
weight of 2-4 g. Histological examination of 6 similar tumors was performed and 
revealed that a constant fraction of 30 + 5% (SE) consisted of necrosis. The tumor 
was considered to be an ellipsoid and its volume was estimated from three 
orthogonal diameter measurements (tumor volume in cubic millimeters = X x Y x Z 
x 0.5) [31]. Mice were divided into groups based on estimated tumor volume and 
stratified randomization was carried out over the different treatment groups. 
Animals which were ill after 3 weeks of tumor growth, i.e. the time of the start of the
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5-FU/modulator treatment, were not used for the experiments. This occurred for 6 
of 73 mice.
Chemotherapy
The tumor-bearing mice received 5-FU at a dose of 115 mg/kg. All drugs were 
administered i.p. as a bolus within 5 seconds. The modulator groups received LV 
(300 mg/kg together with 5-FU, 750 mg/kg 1 h before 5-FU, or twice 375 mg/kg, 
once 1 h before 5-FU treatment and a second time together with the 5-FU), MTX 
(300 mg/kg 1 h before 5-FU administration), IFN (105 IU/animal = ± 4 x 106 IU/kg 24 
h before 5-FU administration), or PALA, (100 or 250 mg/kg 24 h before 5-FU admi­
nistration). The murine recombinant IFN was the kind gift of Schering-Plough 
(Amstelveen, the Netherlands) and PALA was donated by US Bioscience (Watford, 
England). LV and MTX were purchased from Lederle (Etten-Leur, the Netherlands) 
and 5-FU from Roche (Mijdrecht, the Netherlands). Dosage and schedules for 
administration of the various modulators were based on exposure regimens used in 
preclinical studies in mice. The dose of 5-FU used, i.e. 115 mg/kg, is below the 
maximal tolerable dose (150 mg/kg) (32) and corresponds to 350 mg/m in humans 
[33], which lies in the therapeutic range (370-500 mg/m for 5 days) [3]. The 300­
mg/kg MTX dose is relatively high; it corresponds to 925 mg/m in humans (thera-
2
peutic dose, 40-250 mg/m + LV rescue) [14] but was chosen for comparison with 
other 19F NMR studies of combined 5-FU MTX treatment [32]. IFN 105 IU in mice is
5 6equivalent to 3 x 10 IU in humans (therapeutic dose, 2 or 3 times 10 x 10 IU). The
2 2  LV dose of 300 mg/kg (925 mg/m in humans) or 750 mg/kg (2300 mg/m in
humans) used in the second experiment is high compared to the doses used in
patient studies (20-500 mg/m for 5 days) but is based on other preclinical studies
in mice (34, 35). A PALA dose of 100 mg/kg (300 mg/m in humans) is comparable
to a relatively low dose (250 mg/m ) used in patient studies. A 250-mg/kg PALA
2
dose is equivalent to 770 mg/m given to humans [14].
Unless indicated otherwise animals were sacrificed by cervical dislocation 50 
minutes after administration of 5-FU. The tumor was excised within 2 min and
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immediately frozen in liquid nitrogen. The whole tumor was subsequently used for 
extraction.
Perchloric acid extraction
The frozen tissue was pulverized in a liquid nitrogen-chilled stainless steel mortar 
and ground to a fine powder. Per g of pulverized tissue 5 ml of cold 0.9 M perchlo­
ric acid were added, and the sample was stirred with a glass rod and thoroughly 
mixed (1500 rpm, 20 strokes). After homogenization the sample was incubated for 
at least 1 h in a cold chamber on a shaker. The sample was centrifuged, the pellet 
was discarded, and the supernatant was neutralized with KOH and 4% (v/v) of a 
potassium phosphate buffer (pH 6.5, 1 M; final concentration, 40 mM) before 
freeze-drying. After freeze-drying the lyophilisate was dissolved in 0.8 ml 
demineralized water, the pH of the sample was adjusted to 6.5, and the sample 
was freeze-dried again.
19F NMR spectroscopy
19 19F NMR spectra were measured on a Bruker AMX 300 using a dedicated F 
probe as described in detail elsewhere [36]. Freeze-dried sample residues were 
dissolved in 1.6 ml (0.4 M) potassium phosphate, pH 6.5, and placed in a 10-mm
2
NMR tube together with a coaxial insert containing H2O as lock substance, as well 
as parafluorobenzoic acid as an internal standard. Between 3,000 and 50,000 
transients were accumulated, depending on the signal:noise ratio required and the 
concentration of the fluorine-containing compounds in the sample. Data acquisition 
parameters were: spectral width 60,000 Hz; flip angle 30 degrees with a pulse 
width of 5 |js; repetition time 0.75 s; temperature 7°C. Continuous WALTZ-16
1
composite-pulse H decoupling was used at a power level of ca. 0.5 W (90-degree 
pulse = 100 |js). The available fluoropyrimidine reference compounds were purcha­
sed from Sigma (Bornem, Belgium).
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19Analysis of 19F NMR spectra
19The F NMR resonance frequency of 5-FU was set to a chemical shift value of 0 
ppm. The integrals of the signals of 5-FU (F), the FU anabolites (A) (FNuct plus any 
FNucs together), and the FU catabolites (C) (FUPA and FBAL) were calculated by
19comparison of the integrals of their signals to the integral of the F NMR resonance 
of the internal standard p-fluorobenzoic acid (59.20 ppm). Because the 
measurements were performed at relatively low temperature and, thus, high 
viscosity, saturation of the resonances of A, C, and F was not observed. This could 
be derived from an experiment in which the repetition time was set to 9.15 s instead 
of 0.75 s but in which all other parameters were unchanged. Relative comparison 
of the two spectra showed that no increase in signal intensity of the A, C, and F 
peaks was observed with a repetition time of 9.15 s compared to 0.75 s. Only for 
the signal of the internal standard a few percent (5-10%) increase in intensity was 
observed. This implies that under the conditions of the present measurements, the 
influences of T1 effects on signal intensities are lower than the effects of the 
inaccuracy of the integration and the intersample variation. The detection threshold 
corresponds to 2 |j.M in the extract solution. Integrals were determined using the 
Bruker UXNMR software.
Statistics
Group means have been represented with their SE. Differences in group means 
were analyzed by the Student's t test (two sided, a = 0.05) after log transformation 
(log normal distribution). Due to the large number of treatment groups and 
parameters compared to the number of animals, the analysis was kept explorative.
Results
19F NMR detection of tumor 5-FU metabolite patterns
19In the F NMR spectrum of the extract from a tumor treated with 5-FU, shown in 
Fig. 3-2, signals from 5-FU (Peak 3 at 0 ppm) and various anabolites and catabo-
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olites can be observed. In the spectra presented in Fig. 3-2 Peak 2 at 3.44 ppm is 
observed, representing the fluoronucleosides, i.e. 5-fluorouridine (FUrd) and 5-fluo- 
ro-2'-deoxyuridine (FdUrd).
Identification of the resonances of the catabolites DHFU (Peak 6), FUPA (Peak 4) 
and FBAL (Peak 5), respectively, at -33.20, -17.84, and -19.30 ppm, could be 
performed on the basis of literature data [37]. The FNucs (Peak 2) and DHFU 
(Peak 6) resonances are relatively weak and are observed only in spectra with the 
high signal:noise ratios obtained with long accumulation times (50,000 transients). 
Various FNuct peaks (group 1) are observed between 4 and 5 ppm. In most 
spectra four different peaks can be distinguished namely at 4.64 (Peak a), 4.48 
(Peak b), 4.26 (Peak c), and 4.15 (Peak d) + 0.04 ppm (Fig. 3-2, insets). More 
detailed identification of the various nucleotide peaks might be possible on the 
basis of comparison with literature data [37-40]. However, values reported appear 
to vary from one paper to another due to different conditions. Addition of the 
commercially available compound FdUMP to a tumor extract resulted in a signi­
ficant increase of the resonance at 4.26 ppm (Peak c), proving the fact that the 
important anabolite FdUMP underlies this peak region, but probably also other 
FNuct. Addition of FUrd and FdUrd both resulted in an increase of the peak at 3.44 
ppm (Peak 2). Therefore specific identification of the anabolite peaks requires the 
synthesis of appropriate reference compounds.
Time dependence of the tumor 5-FU metabolite pattern
In order to determine the optimal time interval between 5-FU administration and 
tumor excision as well as the best parameter for characterization of the modulator 
effects, tumor extracts obtained at various time intervals after 5-FU administration
19were analyzed by F NMR.
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Fig. 3-2. 19F -spectra of perchloric acid extracts of C38 murine colon tumor tissue excised 50 
min after 5-FU injection (A) without pretreatment or (B) with pretreatment with MTX. Tissue 
quantity: A, 2.3 g; B, 2.5 g; number of scans, 50,000; measurement time, overnight run; 
absolute scales in A and B are directly comparable: Peak 1, FNuct; Peak 2, FNucs; Peak 3, 
5-FU; Peak 4, FUPA; Peak 5, FBAL; Peak 6, DHFU. Inset: Peak 1, four FNuct resonances 
(Peaks a - d); Peak 2, FNucs.
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Fig. 3-3. A, concentration anabolites (A), catabolites (C), and 5-FU (F) in nmol/g tissue in 
extracts of C38 murine colon tumor excised at 0 (<30 s) to 120 min after 5-FU injection. 
Points, mean values of 3-6 animals (17 at 50 min); mean SE was 24%. B, ratio of anabolites 
to catabolites (A/C) and anabolites to total fluorine-containing compounds (A/T). Points, 
mean values of 3-6 animals (17 at 50 min); bars, SE.
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Possible parameters that may reflect the effect of modulators on 5-FU metabolism 
are the absolute concentration of anabolites (A) representing cytotoxicity [8]; of 
catabolites (C) representing detoxification; of total fluorine-containing compounds 
(T) including A, C, and F representing drug uptake [41]; the ratio of anabolites to 5- 
FU (A/F) [11]; of anabolites to catabolites (A/C); and of anabolites to total fluorine- 
containing compounds (A/T) [32]. Fig. 3-3A shows the absolute concentrations of 
A, C, and F as observed at the various time intervals. The results demonstrate that 
A and C increase in a similar parallel way up from 0 (time of 5-FU injection) to 
about 70 min. F increases rapidly within the first 15 min to decrease thereafter. Fig. 
3-3B depicts the values of ratios obtained at increasing time intervals between 5- 
FU administration and section. From the data presented it can be concluded that 
the A/C and A/T parameters become relatively stable for time intervals greater than 
40 min. The A/F ratio does not show a “steady state” period, because F goes to 
zero. Based on these findings it was decided to excise tumors 50 min after 5-FU 
treatment and to take the absolute concentration of A and the A/C and A/T ratios as 
important parameters to study the effects of modulators on 5-FU metabolism, 
although other parameters are also presented.
Effect of modulators on tumor 5-FU metabolite pattern
Fig. 3-2B shows a typical extract spectrum for a mouse treated with MTX and 5-FU. 
With respect to Fig. 3-2A the anabolite peaks are more intense, also in relation to 
the 5-FU and the catabolite peaks. The signals of the FNucts are well resolved. 
However, the distinct FNuct peaks did not show a consistent intensity pattern for 
animals in the same group. Furthermore, no reproducible differences were found 
between various treatment groups. Comparison of the catabolite peaks in the 
spectra of Fig. 3-2 demonstrates that in the MTX cotreatment sample (Fig. 3-2B) 
the FUPA peak (Peak 4) is more intense than the FBAL peak (Peak 5) in contrast 
to the results of 5-FU treatment alone (Fig. 3-2A).
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Table 3-1 Concentration anabolites (A), catabolites (C), 5-FU (F), and total 
fluorine-containing compounds (T) and A/T, C/T, F/T, and A/C ratio's in extracts 
of C38 murine colon tumor tissue excised at 50 min after 5-FU injection
T reatment mg/kg Experi- No. of Metabolite concentrations in nmol/g a tissue ± SE
ment animals A C F T=A+C+F
(1 or 2)
5-FU 115 1 + 2 16 46 ± 5 86 ± 6 39 ± 5 170 ± 12
+ MTX 300 1 8 62 ± 4 b 82 ± 11 51 ± 15 195 ± 18
+ IFN 105 IU 1 7 70 ± 15 77 ± 7 86 ± 29 c 232 ± 44
+ LV 300 1 7 55 ± 5 90 ± 6 40 ± 6 186 ± 4
+ LV 1x750 2 7 30 ± 6 35 ± 7 c 79 ± 20 c 144 ± 20
+ LV 2x375 2 7 37 ± 8 42 ± 11 b 73 ± 13 b 152 ± 18
+ PALA 100 1 7 48 ± 9 100 ± 9 34 ± 8 182 ± 21
+ PALA 250 2 8 29 ± 6 94 ± 23 26 ± 7 148 ± 33
Treatment mg/kg Metabolite ratios ± SE
A/T C/T F/T A/C
5-FU 115 0.26 ± 0.01 0.51 ± 0.03 0.23 ± 0.03 0.57 ± 0.06
+ MTX 300 0.34 ± 0.04 c 0.43 ± 0.05 0.23 ± 0.06 0.90 ± 0.17 c
+ IFN 105 IU 0.30 ± 0.02 0.38 ± 0.05 c 0.32 ± 0.05 0.92 ± 0.17 c
+ LV 300 0.30 ± 0.03 0.49 ± 0.04 0.21 ± 0.03 0.64 ± 0.09
+ LV 1x750 0.20 ± 0.04 0.26 ± 0.07 c 0.54 ± 0.10 b 0.90 ± 0.12 c
+ LV 2x375 0.25 ± 0.04 0.27 ± 0.05 c 0.49 ± 0.08 b 0.94 ± 0.08 b
+ PALA 100 0.26 ± 0.02 0.57 ± 0.04 0.18 ± 0.02 0.48 ± 0.08
+ PALA 250 0.19 ± 0.03 0.64 ± 0.05 c 0.17 ± 0.03 0.33 ± 0.06 c
a Quantities are given in nmol/g of extracted tumor tissue. To achieve absolute amounts in 
nmol, integrals have been multiplied by the conversion factor 104.8 (65.5 uM x 1.6 ml). 
No corrections for partial (5-10%), but constant saturation of the signal of the internal 
standard p -fluorobenzoic acid (long T1) is performed. The signals of A, C, and F did not
show partial saturation effects (see "Materials and methods" for details).
Significantly different from 5-FU alone, P < 0.01, Student's t test. 
c Significantly different from 5-FU alone, P < 0.05, Student's t test.
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This results in a significantly lower FBAL:catabolites (FBAL/C) ratio (0.19 ± 0.05 
compared to 0.51 ± 0.09 for 5-FU alone, P < 0.05), indicating an effect of MTX 
cotreatment on catabolism of 5-FU.
In two series of experiments the effects of the four modulators on the 5-FU 
metabolite pattern of the tumor were determined. The results of the experiments 
are presented in Table 3-1. There was no difference in tumor volume between the 
different treatment groups. Due to relatively large interindividual variation, the SE 
is relatively high for all parameters.
For MTX (300 mg/kg) a significant effect on the tumor 5-FU metabolite pattern was 
observed. Modulation with MTX resulted in a significant increase of the absolute 
concentration of A (62 ± 4 compared to 46 ± 5 nmol/g, P < 0.01) and of the A/C 
ratio observed in the tumor extract (0.90 ± 0.17 compared to 0.57 ± 0.06, P <0.05). 
The total uptake of drug as measured by the parameter T = A + C + F was not 
significantly altered by MTX.
Combination therapy of 5-FU with IFN (10 lU/animal) also led to a significant 
increase of the A/C ratio (0.92 ± 0.17 compared to 0.57 ± 0.06, P < 0.05) and gave 
the highest A levels observed (70 ± 15 compared to 46 ± 5 nmol/g for 5-FU alone, 
P = 0.06). The total concentration of fluorine-containing compounds showed a 
tendency to be increased due to higher levels of unmetabolized 5-FU, but this 
effect was not significant.
Cotreatment of the mice with LV (300 mg/kg together with 5-FU) did not result in 
any significant change in the tumor 5-FU metabolite pattern. In further experiments 
LV was given either 1 h before 5-FU at a dose of 750 mg/kg or as a split dose of 
375 mg/kg 1 h before 5-FU treatment and 375 mg/kg together with the 5-FU. Table 
3-1 also presents the metabolic profiles for these experiments. The results show a 
decrease in A, C, and T and an increase in F, while the A/C ratios for both high­
dose LV cotreatments are comparable to those obtained with MTX or IFN, i.e. 
significantly higher compared to 5-FU alone (0.90 ± 0.12, P < 0.05; and 0.94 ± 0.08, 
P < 0.01, compared to 0.57 ± 0.06).
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The low PALA dose (100 mg/kg 24 h before 5-FU) did not result in changes in the 
5-FU metabolite pattern. With the high PALA dose (250 mg/kg) A, F, and T levels 
are reduced, the FBAL/C ratio is significantly increased (1.19 ± 0.27 compared to 
0.51 ± 0.09, P < 0.05) indicating an alteration in relative rates of individual catabolic 
steps. Also, a significant reduction in the A/C ratio is seen (0.33 ± 0.06 compared to 
0.57 ± 0.06, P < 0.05).
Discussion
19In the present study F NMR analysis of extracts of 5-FU treated tumors was 
demonstrated to be a useful model system for studies of modulator effects on 5-FU
19metabolite patterns. Only a few F NMR extract studies of 5-FU treated tumors 
have been reported [8,11,42,43]. El-Tahtawy et al. [43] reported in vivo and in vitro 
measurements of intratumoral metabolism of 5-FU modulated by MTX. Most of the
19F NMR studies on modulator effects on 5-FU metabolism in animals or humans 
have been carried out in vivo, testing only one modulator in combination with 5-FU, 
such as, e.g., MTX [12,32,44], IFN [13], LV [15], thymidine [40,45], choline orotate 
[46], and allopurinol (also tested in vitro) [11]. In addition, some modulators have
19been tested by F NMR analysis in cell cultures [37]. The possible influence of
19PALA on 5-FU metabolism had not been studied yet by F NMR. Thus, to our 
knowledge, the present study is the first one that reports on the effect of various 
modulators of 5-FU metabolism on tumor metabolite patterns in one and the same 
experimental model. Our results demonstrate that the effectiveness of the various 
modulators, especially LV and PALA, is dependent on the applied exposure 
regimen. This phenomenon has been reported before for modulator effects on 5- 
FU metabolism [14,34,35,47]. The exposure regimens that brought about these 
modulating effects were generally comparable to exposure regimens applied in 
clinical treatments or trial studies with 5-FU treated patients (see “Materials and 
methods” for details).
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In the MTX group the absolute A concentration was significantly higher than that 
obtained with 5-FU alone, while F and C remained unchanged. This result shows 
that MTX cotreatment improves the A/C ratio by increasing the tumor concentration 
of therapeutically active 5-FU-derived nucleotides. This positive effect of MTX has
19been described before in clinical studies on 5-FU therapy [18] and in in vivo F 
NMR studies [12,32,44]. Cotreatment with MTX is presently used in the clinic for 
improved 5-FU therapy response. It is the only combined treatment modality with a 
significant effect on survival. Thus our tumor extract model supports this positive 
modulator effect of MTX. Positive effects of IFN [20] and LV [19] on 5-FU therapy 
have also been reported in clinical trials. The increase in A/C ratio for IFN was due 
to an increase in mean A concentration, although this increase did not meet the 
significance criterion because of a large SE. In the high-dose leucovorin group of 
the present study, an increase in the A/C ratio was observed due to a large 
decrease in C and a smaller decrease in A. This treatment group had low T and 
high F levels, indicating reduced drug uptake and reduced anabolism and 
catabolism.
Finally, the effect of cotreatment with a high dose of PALA is remarkable. This 
finding may be compatible with reported resistance of 5-FU treatment to PALA 
modulation [47,48]. However, other studies have mentioned an improved 
therapeutic index with this combination [18]. In theory the observed decline in A 
concentration and A/C ratio observed in the present study might be explained by a 
reduction in the concentration of UTP as a result of the PALA-induced depletion of 
its precursor orotic acid. Reduced levels of UTP may then enhance FUTP 
incorporation into RNA with an increased therapeutic effect accompanied by a 
decrease in the observed concentration of free FUTP. To solve this matter is an 
important topic for future research including measurements of the fluorinated 
products in the RNA, thymidylate synthase, and DNA fractions.
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Abstract
19High-resolution F NMR spectroscopy at 9.4 T was used to study the difference in 
the metabolite pattern of 5-fluorouracil (5-FU) between viable and necrotic tissues 
of C38 murine colon tumors grown in C57Bl/6 mice. Studies were performed on 
perchloric acid extracts of these tumor fractions after 5-FU treatment.
19The F nuclear magnetic resonance spectra exhibited resonances representing 5- 
FU, the catabolites a-fluoro-G-ureidopropionic acid and a-fluoro-R-alanine, as well 
as several fluoronucleotide anabolites. The absolute concentrations of anabolites 
and catabolites and the anabolite-to-catabolite ratio were significantly lower in the 
necrotic fraction than in the viable tumor fraction 50 min after administration of 5- 
FU, whereas the absolute concentration of 5-FU was the same. Therefore, in 5-FU 
metabolism studies with NMR spectroscopy, it is important to consider the necrotic 
contribution to the tumor volume.
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Introduction
5-Fluorouracil (5-FU) is still the most important cytostatic drug in the treatment of 
colorectal cancer [1]. To perform its cytostatic effect, it has to be converted into 
active anabolites [2]. Furthermore, 5-FU is degraded to inactive catabolites. The 
first conversion occurs predominantly in tumor cells, the second mostly in the liver 
[3]. Only a small percentage of the 5-FU is taken up in tumor cells and converted 
to the therapeutically important anabolites: the fluoronucleosides (FNucs) and 
fluoronucleotides (FNuct). The functionally most important FNuct are 5-fluoro-2'- 
deoxyuridine 5'-monophosphate (FdUMP) and 5-fluorouridine 5'-triphosphate 
(FUTP), the latter generally occurring at a much higher concentration [4]. A large 
fraction of the administered 5-FU is degraded to catabolites of which 5,6-dihydro- 
5-fluorouracil (DHFU), a-fluoro-G-ureidopropionic acid (FUPA), and a-fluoro-G- 
alanine (FBAL) are the most important. Although it is generally agreed upon that 
the FNuct formed as a result of anabolism are responsible for the therapeutic 
effect of 5-FU, the precise mechanism underlying the antitumor activity of the 
FNuct is still a matter of debate [1, 2].
To understand the effectiveness of 5-FU, its metabolism has been studied in
19several tumor models and in patients. F NMR spectroscopy is one of the 
methods to monitor the presence of 5-FU and a number of its anabolites and 
catabolites in tumor tissue [4]. We have recently used this method to demonstrate 
the effect of various biomodulators on 5-FU metabolism in murine colon 
carcinomas [5]. In vivo NMR studies have actually correlated FNuct levels with 
therapeutic response [6-8]. Commonly, in these studies, whole tumors are 
investigated and the amount of necrosis is neglected, although tumors may con­
tain various quantities of necrosis that could affect the results.
The objective of the present study was to investigate to what extent the amount of
19necrosis affects F NMR spectral profiles. The level of 5-FU and its metabolites 
may be different in the necrotic part, compared with the viable part of the tumor. 
To address this problem, viable and necrotic parts of a murine colon tumor were
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19separated after administration of 5-FU and F NMR spectra of exracts of this 
material were measured.
Materials and methods 
Tumor model
Female C57BL/6 mice of 8 to 12 weeks of age were obtained from the Central 
Animal Laboratory of our university. The C38 murine colon tumor, which is known 
to be sensitive to 5-FU, was acquired from Dr. P. Lelieveld of the REPGO-TNO 
Institute (Rijswijk, the Netherlands) and is described elsewhere [9]. Tumor tissue 
fragments with a diameter of 3 mm were implanted subcutaneously in the right 
flank of the mouse. To investigate the influence of tumor size and thereby amount 
of necrosis, three groups of tumors of different weight were measured. In the first 
group (n = 6), the experiment was performed after 20 days, when the tumors 
reached a weight of 1.9 (mean) + 0.2 g (SE) necrosis included; in the second 
group (n = 8) after 27 days, with a total tumor weight of 4.6 + 0.6 g; and in the third 
group (n = 2) after 34 days, with a total tumor weight of 7.0 + 0.05 g. No functional 
compromise of the mouse by the tumor burden was observed. In addition, to get 
insight in the pharmacokinetics of 5-FU, a time curve with respect to time after 5- 
FU administration was determined for 5-FU, anabolites and catabolites for the first 
weight group with the smallest tumors. The tumor was considered to be an ellip­
soid, and its volume was estimated from three orthogonal diameter measurements 
(tumor volume in cubic millimeters = X x Y x Z x 0.5) [9]. For the time curve, mice 
were divided into groups based on estimated tumor volume, and stratified 
randomization was conducted over the different time groups.
Chemotherapy
At the time of the experiment, the tumor-bearing mice received 5-FU at a dose of 
115 mg/kg as bolus i.p. within 5 s. 5-FU was purchased from Roche (Mijdrecht,
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the Netherlands). The dose of 5-FU used (i.e. 115 mg/kg) is below the maximal 
tolerable dose (150 mg/kg) [10] and corresponds to 350 mg/m in man [11], which 
lies in the therapeutic range (370-500 mg/m for 5 days) [12].
Animals were killed by cervical dislocation 50 min after administration of 5-FU, 
except for the time curve study, because the various concentrations were 
measured at different time points. This time point was chosen because of active 
and considerable metabolite formation, as followed from a time curve of whole 
tumors in our previous study [5]. The tumor was excised within 2 min and cleaved 
on ice to separate the necrotic tissue from the viable tumor tissue. Viable tumor 
and necrotic tissues were immediately frozen in liquid nitrogen until further 
processed by perchloric acid (PCA) extraction.
PCA extraction
The frozen tissue was pulverized in a liquid nitrogen-chilled stainless steel mortar 
and ground to a fine powder. Per gram of pulverized tissue, 5 ml of cold 0.9 M 
PCA was added, and the sample was stirred with a glass rod and thoroughly 
mixed (1,500 rpm, 20 strokes). After homogenization, the sample was incubated 
for at least 1 h in a cold chamber on a shaker. The sample was centrifuged, the 
pellet was discarded, and the supernatant was neutralized with KOH and 4% (v/v) 
of a potassium phosphate buffer (pH 6.5, 1 M, final concentration 40 mM) before 
freeze-drying. After freeze-drying, the lyophilisate was dissolved in 0.8 ml of 
demineralized water, the pH of the sample was adjusted to 6.5, and the sample 
was freeze-dried again.
19F NMR spectroscopy
19 19F NMR spectra were measured on a Bruker AMX 400 using a dedicated F 
probe. Freeze-dried sample residues were dissolved in 0.4 ml demineralized water 
and placed in a 5-mm NMR tube, together with a coaxial insert containing H2O as 
lock substance, as well as parafluorobenzoic acid as an internal standard. 
Between 3,000 and 30,000 transients were accumulated, depending on the signal-
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to-noise ratio required and the concentration of the fluorine-containing compounds 
in the sample. Data acquisition parameters were: sweep width 60 kHz; flip angle ~
1
45° with a pulse width of 6 |js; repetition time 1.5 s; and temperature 298°K. No H 
decoupling was used.
19Analysis of 19F NMR spectra
19The F NMR resonance frequency of 5-FU was set to a chemical shift value of 0 
ppm. The integrals of the signals of 5-FU (F), the FU anabolites (A) (FNuct plus 
any FNucs together), and the FU catabolites (C) (FUPA and FBAL) were
19calculated by comparison of the integrals of their signals to the integral of the F 
NMR resonance of the internal standard parafluorobenzoic acid (59.02 ppm). 
Under the current conditions, no important saturation of the resonances of A, C, 
and F was observed. This is concluded from an experiment in which the repetition 
time was set to 9 s instead of 1.5 s, but in which all other parameters were left 
unchanged. Relative comparison of the two spectra showed that the highest 
increase in signal intensity was observed for the internal standard when the 
repetition time was changed from 1.5 to 9 s. The internal standard was calibrated 
by adding a known concentration of 5-FU to an untreated tumor extract holding the 
reference capillary. The detection threshold of fluorinated compounds is estimated 
to be ~3 |j.M in the extract solution. Peak areas were obtained by fitting a 
Lorentzian model function using NMR1 software (New Methods Research, Inc., 
Syracuse, NY).
Statistics
For each group, mean values of concentrations have been presented with their 
standard error of the mean (SE). Differences in mean values between viable and 
necrotic tumor fractions were analyzed by the paired f-test (two-sided, a = 0.05) 
after log transformation [13].
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Results
19F NMR detection of 5-FU metabolite patterns in viable and necrotic tumor 
tissue
19Fig. 4-1A presents the F NMR spectrum of the extract of viable tumor tissue of a 
mouse 50 min after 5-FU treatment. In addition to the peak of 5-FU (Peak 2 at 0 
ppm), anabolite and catabolite peaks are seen. Various FNuct peaks indicated 
with 1 are observed between 3 and 5 ppm. In most spectra, three, sometimes four, 
different peaks can be distinguished, namely at 4.57 + 0.03, 4.31 + 0.03, 3.77 + 
0.00 and 3.74 + 0.06 (not visible in Fig. 4-1) ppm (+ mean deviation). More detai­
led identification of the various nucleotide peaks might be possible on the basis of 
comparison with literature data [14-16] and with our own identification of FdUMP 
(small right peak from Group 1) and of the nucleoside peaks 5-fluorouridine (FUrd) 
and 5-fluoro-2'-deoxyuridine (FdUrd) (upfield from Group 1; not visible in Fig. 4-1) 
[5]. However, chemical shifts reported seem to vary from one publication to 
another, because of the variation in sample conditions. Specific identification of the 
other anabolite peaks requires the synthesis of appropriate reference compounds. 
For anabolites, the area under the curve of the total FNuct peak at ~4 ppm is 
taken. At -17.01 + 0.11 and -18.61 + 0.10 ppm, upfield from 5-FU, two catabolite 
peaks are seen: FUPA (Peak 3) and FBAL (Peak 4), respectively. Sometimes 2 
other small catabolite peaks are visible at -33 ppm (DHFU) and at 49 ppm (F- 
cations), not shown in this spectrum. The main amount of catabolites, however, is 
composed of FUPA and FBAL, which in this study are referred to the catabolites. 
Fig. 4-1B presents the spectrum of the extract from the excised necrotic area 
belonging to the same tumor. The spectrum shows signals for the major 
compounds also observed in the spectrum of the viable tumor tissue extract. 
However, relative and absolute signal intensities are clearly different.
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Fig. 4-1. 19F spectra of PCA extracts of C38 murine colon tumor tissue grown for 20 days 
after transplantation and excised 50 min after 5-FU injection: (A) viable tumor tissue and (B) 
necrosis. Tissue quantity: A, 2.0 g; B, 0.85 g; number of scans, 4,000; measurement time,
2 h; Peak 1, three FNuct resonances; Peak 2, 5-FU; Peak 3, FUPA; Peak 4, FBAL.
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Table 4-1 Concentration anabolites (A), catabolites (C), 5-FU (F), and total fluorine-containing 
compounds (T) and ratios A/T, C/T, F/T, and A/C in extracts of viable tumor tissue 
and necrosis of C38 murine colon tumor excised 50 min after 5-FU injection
Tumor No.of Metabolite concentrations in nmol/gc tissue ± SE
Tissue a
Q
Weightb animals A C F T=A+C+F
Viable
Necrotic
20 1.3 + 0.2 
0.5 + 0.1
6 107±1 4d 
23 ± 8
106 ± 16e 
68 ± 9
55 ± 18 
64 ± 15
268 ± 32d 
155 ± 19
Viable
Necrotic
27 3.3 + 0.4
1.4 + 0.3
8 81 ± 14d 
24 ± 8
100 ± 12 
51 ± 10
90 ± 24 
70 ± 19
271 ± 38d 
145 ± 31
All tumors togetherf 
Viable 
Necrotic
2.7 + 0.4 
1.2 + 0.2
16 88 ± 10d 
26 ± 5
e
104 ± 8e 
64 ± 8
75 ± 15 
68 ± 11
266 ± 22d 
157 ± 18
Metabolite ratios ± SE
Weight A/T C/T F/T A/C
Viable
Necrotic
CO 
LO 
O
e
0.40 ± 0.02e 
0.15 ± 0.05
0.41 ± 0.06 
0.46 ± 0.07
0.19 ± 0.05d 
0.39 ± 0.05
e
1.11 ± 0.22e 
0.43 ± 0.17
Viable
Necrotic
3.3
1.4
0.28 ± 0.05 
0.14 ± 0.03
0.43 ± 0.08 
0.41 ± 0.10
0.28 ± 0.06 
0.46 ± 0.09
0.87 ± 0.19 
0.54 ± 0.14
All tumors together 
Viable 
Necrotic
2.7
1.2
0.32 ± 0.03d 
0.14 ± 0.02
0.43 ± 0.05 
0.44 ± 0.05
0.25 ± 0.04d 
0.42 ± 0.05
0.91 ± 0.13d 
0.48 ± 0.09
a Days after tumor transplantation. 
b Weight of viable tumor tissue and necrosis separately.
c Quantities are given in nmol/g of extracted tissue. To achieve absolute amounts in nmoles, 
integrals have been multiplied by the conversion factor 104.8 (262 uM x 0.4 ml). 
d Significantly different, P  < 0.01.
e
Significantly different, P  < 0.05. 
f Including the third group (34 days, n = 2) not shown separately.
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Parameters for response to treatment
Possible parameters that may reflect the effectiveness of 5-FU treatment are the 
absolute concentration of anabolites (A) representing cytotoxicity [4], of catabolites 
(C) representing detoxification, of total fluorine-containing compounds (T) 
including A, C, and F [14], the ratio of anabolites to 5-FU (A/F) [6], of anabolites to 
catabolites (A/C), and of anabolites to total fluorine-containing compounds (A/T) 
[10]. In the present study, these parameters were evaluated both in viable and 
necrotic tumor tissue.
Table 4-1 summarizes the evaluation of all data at 50 min after 5-FU injection. 
From the table, it follows that in viable tumor tissue the absolute concentration of A 
is significantly higher than in the necrotic area. For the three weight groups 
together, these values are 88 + 10, compared with 26 + 5 nmol/g, P < 0.01. This is 
also the case for the absolute concentration of C (104 + 8, compared with 64 + 8 
nmol/g, P < 0.05), but not for the absolute concentration of F that seem s similar in 
tumor and necrosis (75 + 15, compared with 68 + 11 nmol/g). The total 
concentration of fluorine-containing compounds T is higher in the tumor fraction, 
compared with necrosis (266 + 22, compared with 157 + 18 nmol/g, P < 0.01). 
Because of the different relative changes between tumor and necrosis of 
metabolite concentrations, some of the metabolite ratio's are also different. Higher 
values are found in tumor tissue for the A/C ratio (0.91 + 0.13, compared with 0.48 
+ 0.09, P < 0.01) and the A/T ratio (0.32 + 0.03, compared with 0.14 + 0.02, P < 
0.01). The F/T ratio is even significantly lower in the tumor fraction (0.25 + 0.04, 
compared with 0.42 + 0.05, P < 0.01). The sam e tendency is seen in the separate 
weight groups.
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A
time (min)
C
B
4001
time (min)
D
time (min)
Fig. 4-2. (A-D) Concentration anabolites (A), catabolites (C), 5-FU (F), and total fluorine- 
containing compounds (T) in nmol/g tissue in extracts of C38 murine colon tumor (mean 
total tumor weight 1.8 g) excised 0 (<30 s) to 120 min after 5-FU injection (n = 6, mean + 
SE).
.......... , viable tumor tissue; --------- , necrotic tissue.
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Histological determination of percentage viable tumor cells in tumor and 
necrotic fractions
Although viable tumor and necrosis clearly can be divided macroscopically, it is 
obvious that a perfect separation of pure tumor and necrotic material is not 
possible. Histological examination of the tumors of the first group (plus two extra) 
and of two tumors of the second group was performed; it was revealed that ~70% 
(first group) of the tumor fraction consisted of viable tumor cells and 30% of the 
necrotic fraction. For the two tumors of the second group, these percentages were 
in the sam e range.
Time dependence of 5-FU metabolite pattern in tumor and necrotic tissue
To determine the time course of 5-FU metabolism in viable and necrotic tumor 
tissues, 20 days after transplantation, when the tumors had reached a mean total 
weight of 1.8 g, tumor extracts from both parts obtained at various time intervals
19after 5-FU administration were analyzed by F NMR. The results of these 
experiments are presented in Fig. 4-2. Fig. 4-2 (A-D) shows the absolute concen­
trations of A, C, F, and T as observed at the various time intervals. The results 
demonstrate that F increases rapidly within the first 15 min, especially in the viable 
tumor part, to decrease thereafter. A and C increase in a similar parallel way up 
from 0 (time of 5-FU injection) to ~70 min. After an initial increase and a smaller 
decline thereafter, T stays at a stable level for the first 2 h. The tendencies are the 
same for the viable and necrotic tumor part. In the latter, the absolute values, 
except the concentration of F, are lower most of the time. This is particularly the 
case for the period after 50 min.
94
5-fluorouracil metabolism in tumor and necrosis
Discussion
19Only a few F NMR extract studies of 5-FU-treated tumors have been reported [4­
196, 17, 18]. Most of the F NMR studies on 5-FU metabolism in animals or man
19have been conducted in vivo. In addition, F NMR analysis has been performed in 
cell cultures [19]. The role of necrosis in the interpretation of results of 5-FU
19metabolism has not been studied yet by F NMR. Because 5-FU metabolite levels 
may be quite different in necrotic parts, compared with viable parts of a tumor, the
19necrotic fraction may contribute significantly to the F NMR spectral profile of a 
tumor. This is of importance not only for in vitro studies, but especially for in vivo 
studies. In this study we have attempted to characterize a possible difference in 5- 
FU metabolite levels between necrotic and tumor fractions of a murine colon 
carcinoma.
In the necrotic fraction of the tumor, the absolute concentrations of all metabolites 
were lower than in the viable tumor fraction. The initial higher increase of 5-FU in 
viable tumor parts, compared with necrotic parts, most likely is caused by better 
vascularization of viable tumor tissue. After ~30 min, however, 5-FU levels 
become similar in both parts. Various processes may contribute to this behaviour. 
Diffusion of 5-FU into necrotic tissue will occur, but at the same time 5-FU is better 
cleared from the well-vascularized, viable part of the tumor. Another process may 
be acidification of the viable cells in the necrotic part, inducing local retention of 5- 
FU [20]. Whatever the responsible mechanism may be, the results indicate that 5- 
FU permeates into the necrotic area to a similar level as in the viable tumor area. 
Anabolite levels are higher in tumor parts than in necrotic parts, which could be 
expected on the basis of the metabolic activity in viable tumor cells. Diffusion 
processes apparently are not able to equalize anabolite levels among viable and 
necrotic tumor parts. Considering the amount of viable tumor cells still present in 
the necrotic fraction, it is conceivable that an appreciable part of the anabolites in 
this fraction arise from these cells. In this tumor model, the amount of necrosis 
seem s not of major importance for the response to therapy, because 5-FU
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reaches also the necrotic fraction wherein the viable cells anabolites can be 
formed.
Because catabolites are produced predominantly by detoxification of 5-FU in the 
liver, the well-vascularized part of the tumor will be supplied by increasing 
amounts of these catabolites, as is observed in this study. The lower levels of 
catabolites in the necrotic part of the tumor are likely caused by bad 
vascularization, which is not sufficiently compensated by diffusion from viable 
tumor parts.
It is common practice in animal studies to take tumors not exceeding 10% of body 
weight. This because of the possible occurrence of anaemia influencing tumor 
perfusion (viscosity) and oxygenation, and functional compromise by the tumor 
burden [21]. As a result, substantial necrosis may develop. From this study, it 
follows that, in a tumor with a significant amount of necrosis, the conversion from 
5-FU to anabolites and catabolites may be underestimated, as well as the A/C 
ratio. Therefore, it is of importance in 5-FU metabolism studies either to limit the 
amount of necrosis or to consider a possible contribution of necrosis.
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Abstract
To determine whether carbogen breathing has an effect on 5-fluorouracil (5-FU) 
uptake, retention and metabolism in C38 murine colon tumours grown in C57Bl/6
19mice, we used in vivo F nuclear magnetic resonance (NMR) spectroscopy.
Eleven tumour-bearing mice were treated with 150 mg/kg of 5-FU given
intraperitoneally (i.p.). Five mice received carbogen gas (95% O2 and 5% CO2) for
9.5 min, starting 1 min before 5-FU administration. We found increased levels of 5­
19FU and its anabolites and catabolites by sequential F NMR spectroscopy in the 
group treated with 5-FU in combination with carbogen compared with the group 
treated with 5-FU alone. The maximum of normalised values of 5-FU and its 
metabolites, reached after carbogen breathing, was almost 2-fold higher than after 
treatment with 5-FU alone. Despite these increased concentrations no significant 
effect of carbogen on growth inhibition of the tumour by 5-FU was observed, which 
may be related to the size as well as the well vascularised and perfused conditions 
of the tumours studied.
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Introduction
Colorectal cancer is one of the most common cancers in the western world. 
Moreover, a significant number of patients develop metastases and will die of the 
disease. Treatment of advanced colorectal cancers with chemotherapy is difficult. 
Only 20-30% of patients will respond to treatment with 5-fluorouracil (5-FU), the 
main cytostatic agent for this disease. It is also difficult to predict whether a patient 
will respond to treatment or not. Strategies to improve treatment outcome which are 
already used in clinical practice are biomodulation of 5-FU, administration by conti­
nuous infusions or hepatic arterial infusion instead of bolus injections [1-3]. In an 
earlier study, we observed that certain biomodulators of 5-FU metabolism 
increased the tumour levels of anabolites or the ratio of anabolites to catabolites [4]. 
To exert their effect, cytostatics should reach and enter the tumour cells. In tumours 
with poorly perfused areas this may become a limiting factor and treatment of these 
tumours may benefit from perfusion-enhancing approaches. Modulation of the 
oxygenation of tumours has been attempted by breathing carbogen (95% O2, 5% 
CO2). It has been reported that carbogen raises distending pressure in capillaries 
by increasing systemic arterial blood pressure and decreasing the tone of 
resistance of arterioles [5]. Carbogen breathing produces in some cases an 
increase in blood flow / perfusion [6]. The heterogeneity in blood flow increase 
highlights the disordered structure of tumour vascular architecture. In Morris 
hepatoma, carbogen breathing increased both tumour pO2 and magnetic 
resonance (MR) image intensity which is sensitive to changes in deoxyhaemoglo- 
bin [7]. No changes were seen in blood flow measured by laser Doppler flowmetry. 
This in contrast with other tumour types, where carbogen has been shown to 
change tumour blood flow, suggesting that this may be a tumour-specific phenome­
non [8]. Carbogen is applied in experimental settings in the field of radiotherapy in 
order to increase the pO2 and radiosensitivity of tumours [9]. Carbogen breathing is 
often combined with the use of perfluorochemical emulsions (PFCE) as an adjuvant 
to radiation or chemotherapy [10]. The rationale is that solid tumour masses contain
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areas of hypoxia which are therapeutically resistant. Several anticancer agents are 
enhanced in antitumour activity by the co-administration of PFCE and carbogen. As 
carbogen breathing may affect tumour blood perfusion, it could also serve as a tool 
to enhance the uptake of antitumour compounds like chemotherapeutics, such as 
cyclophosphamide, ifosfamide and 5-FU. With carbogen breathing tumour growth 
delay by cyclophosphamide is enhanced [11]. In addition, it has been shown that 
carbogen breathing increases the uptake and cytotoxicity of ifosfamide in rat
19prolactinomas [12]. Recently it has been demonstrated by 19F nuclear magnetic 
resonance (NMR) spectroscopy that carbogen breathing increases 5-FU uptake 
and cytotoxicity in hypoxic murine RIF-1 tumours [13]. Carbogen may also exert its 
effect by changing the extracellular pH. It is known that cellular uptake of 5-FU is 
pH-dependent [14]. After carbogen breathing a fall in the extracellular pH is obser­
ved, which can cause an increased 5-FU uptake.
The purpose of this study was to determine the effect of carbogen breathing on the 
pharmacodynamics of 5-FU uptake in the C38 murine colon tumour monitored by
19F NMR spectroscopy. Furthermore, the effect of carbogen breathing on tumour 
growth inhibition by 5-FU was studied.
Materials and methods
Chemicals
5-FU was obtained from Teva (Mijdrecht, the Netherlands) as a saline solution at 
50 mg/ml. Carbogen gas (95% O2-5% CO2) was obtained from Hoekloos 
(Schiedam, the Netherlands).
Tumour model
Female C57BL/6 mice of 8-12 weeks of age were obtained from the Central Animal 
Laboratory of our university. The C38 murine colon tumour, which is known to be 
sensitive to 5-FU, was acquired from Dr. P. Lelieveld of the REPGO-TNO Institute,
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Rijswijk, the Netherlands, and is described elsewhere [15]. Tumour tissue 
fragments with a diameter of 3 mm were implanted subcutaneously (s.c.) in the 
right flank of the mouse. Treatment was performed after 2 weeks, when the 
tumours reached a weight of 0.4-0.8 g. The maximum tumour size was < 7% body 
weight. The tumour was measured with a calliper. The tumour was considered to 
be an ellipsoid and its volume was estimated from three orthogonal diameter 
measurements using the following formula: tumour volume (mm ) = X x Y x Z x 0.5 
[15]. The experimental procedures were approved by the local ethics committee for 
the use of animals.
Treatment
At the time of the experiment the tumour-bearing mice were cannulated 
intraperitoneally (i.p.) with polythene tubing (inner diameter 0.4 mm, outer diameter 
1.8 mm) under inhalation anaesthesia using a mixture of enflurane (1.5%), oxygen 
(29.5%) and nitrous oxide (69%) applied through a nose-cone and positioned in the 
magnet. The temperature of the mice was maintained at 37 0C using a warm water 
blanket with a feedback system and controlled with a rectal temperature probe. To 
determine whether carbogen breathing causes an effect on the pharmacodynamics 
of 5-FU, the following experiment was performed. After shimming, carbogen breat­
hing (2 l/min) was switched on for 9.5 min, whilst turning off the nitrous oxide and 
oxygen. After the first minute of carbogen breathing 5-FU was administered as a 
bolus i.p. at a dose of 150 mg/kg in normal saline (0.1 ml/g) within 20 s. At the
19moment of 5-FU administration F NMR was also started. At the end of the first 
block of 8.5 min, so after 9.5 min in total, carbogen was switched off and replaced 
by oxygen and nitrous oxide again. The dose of 5-FU used, i.e. 150 mg/kg, is well 
tolerated and corresponds to 457 mg/m in man, which is in the therapeutic range 
(370-500 mg/m for 5 days) [16]. A total of five mice were treated in this way. The 
same procedure was applied to a control group of tumour-bearing mice (n = 6) but 
omitting the carbogen.
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Carbogen was given during 9.5 min. This duration was based on the following 
findings. After 1 min of carbogen breathing the oxyhaemoglobin concentration and 
deoxyhaemoglobin concentration in human glioma xenografts are close to a steady 
state [8]. Therefore carbogen breathing was started 1 min before 5-FU adminis­
tration. Upon carbogen breathing an increasing tumour pO2 has been reported in 
both animals and patients, which is maximal in patients after 1-6 min [17]. Return to 
precarbogen levels of oxygenation occurred in 1 min after the end of gas exposure
[18]. In clinical radiotherapeutical studies, carbogen breathing is applied 4 min 
before and also during radiotherapy, in total for approximately 15 min [9]. Within 
approximately 10 min carbogen breathing reaches its maximal effect. Because we 
wanted to obtain tumour trapping of 5-FU after bolus injection by inducing a short 
vasodilatation by means of carbogen, carbogen breathing was continued for one 
block of 8.5 min, in total for 9.5 min.
19F NMR spectroscopy
19F NMR spectra were measured at 169.457 MHz on a 4.3 Tesla (T) Oxford vertical
1 19bore magnet equipped with a SMIS console. A home-built H/ F double tunable 
radiofrequency (RF) coil with an internal diameter of 13 mm and two windings was 
placed around the tumour. The RF coil was fitted with a Faraday shield to eliminate 
spurious signals from normal tissue adjacent to the tumour. Shimming was per­
formed until a H2O signal line width at half-height of less then 70 Hz was obtained.
19F NMR data acquisition parameters were: spectral width 10 kHz, repetition time
0.5 s, flip angle 90° with a rectangular RF pulse of 20 |js. No H decoupling was 
used. Spectra were recorded from the moment of 5-FU injection. Measurements 
took place during 2 h in blocks of 8.5 min, in which 1024 acquisitions or 
measurements were recorded.
Before and after this session a H NMR spectrum at 180.130 MHz was recorded by
19the F coil for quantification using the signal of H2O as an internal reference. Sixty- 
four scans were recorded with a repetition time of 1 s. Because the H NMR spec-
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tra were recorded before and 2 h after the carbogen breathing, the influence of 
carbogen breathing on the relaxation of the H spins of water was excluded.
19Analysis of F NMR spectra
19The F NMR resonance frequency of 5-FU was set to a chemical shift value of 0 
parts per million (ppm). The integral for the signals of 5-FU (F), the FU anabolites 
(A), and the FU catabolites (C) (a-fluoro-G-ureidopropionic acid [FUPA] and a-
19 1fluoro-R-alanine [FBAL]) was determined. Signals in F and H NMR spectra were 
quantitated by iterative fitting of the time domain signal with the variable projection 
method (VARPRO) using MRUI software [19,20]. All the peak areas were obtained 
by fitting the spectral lines to Lorentzian line shapes. The catabolite content was
19determined as the sum of the FUPA and FBAL signal intensities. All F curves are 
normalised by dividing the integrals by the mean integral of the H2O signal in the 
two H spectra. This assumes that the amount of hydrogen measured is correlated 
with the amount of measured tumour tissue, taking into account that a constant part 
of the tumour (85-90%) consists of water. By this semi-quantitative method it is 
possible to compare metabolite levels between the different treatment modalities. 
The area under the concentration-time curve (AUC) for A, C and F was calculated.
Tumour histology
Tumour sections were also offered for histological examination. Special attention 
was given to the presence of necrosis.
Tumour vascularity and perfusion
Six separate mice (without any treatment) were studied for tumour vascularisation 
and perfusion. This method has been described by Rijken and colleagues [21].
Tumour growth
All mice were followed for tumour volume and body weight after the spectroscopy 
experiment plus nine additional ones receiving 5-FU alone plus an additional one
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receiving 5-FU plus carbogen. Those two parameters were determined twice a 
week for a period of 4 weeks. In order to compare tumour growth, the relative 
tumour volumes were taken. Therefore, reference was made to the value obtained 
on day 0, which was the day of treatment. At the end of the experiment the mice 
were sacrified.
Statistics
The spectroscopy experiment was performed on six mice who received 5-FU alone 
and five mice who received 5-FU together with carbogen breathing. For each group 
of mice medians are presented with the minimum and maximum for the 
spectroscopy parameters. Differences between the two groups were analysed by 
the unpaired Student f-test. For the parameters under Cmax concerning maximum 
concentration, tests were performed after log transformation, because of oblique 
distribution. For the parameters under AUC concerning surface, tests were perfor­
med after root transformation. A two-sided significance level of 0.05 was used. For 
the half life (t1/2) of 5-FU the Wilcoxon 2-sample test was used.
The experiment concerning tumour growth inhibition was performed on 15 mice 
who received 5-FU alone and six mice who received 5-FU together with carbogen 
breathing. To express the growth rate after the minimal tumour volume was 
reached, the tumour volume doubling time was calculated on the assumption of 
exponential growth. Parameters concerning tumour volume (growth) were analysed 
after log transformation.
Results
19Comparison of F NMR in vivo serial spectra of C38 colon tumour with and 
without carbogen breathing
19In sequential F NMR spectra of C38 tumours after administration of 5-FU, signals 
from 5-FU and its anabolites and catabolites could be observed (Fig. 5-1).
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Fig. 5-1. Effect of carbogen breathing on the 19F nuclear magnetic resonance (NMR) spectrum 
of a C38 murine colon tumour. Shown are sequential spectra at 17 min intervals (two spectra of 
8.5 min summed) after intraperitoneal (i.p.) injection of 150 mg/kg 5-FU. Plotted beside each 
spectrum is the time in min of the acquisition interval after injection of 5-FU. (A) Treated with 5- 
FU alone; and (B) treated with 5-FU plus carbogen breathing during the first 8.5 min. A, 
anabolites; C, catabolites; F, 5-FU.
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The 5-FU peaks, and its anabolite and catabolite peaks were often higher in the 
presence of carbogen. The 5-FU signal almost completely disappeared one hour 
after its application, both in the absence and in the presence of carbogen. The 
anabolites were presented as one single peak (peak A between 4.5 and 5 ppm). 
The catabolites were reflected by two different peaks, the first representing FUPA 
and the second representing its conversion product FBAL (peaks C between -16.5 
and -17 ppm and between -18 and -18.5 ppm).
Time dependence of the tumour 5-FU metabolite pattern with and without 
carbogen breathing
Carbogen breathing resulted in a more rapid increase to a higher level of 5-FU in 
the tumour. Also the levels of its anabolites and catabolites were enhanced (Table 
5-1). As a consequence the total amount of fluorine-containing compounds was 
higher as well. 5-FU increased during the first 17 min and decreased thereafter 
within two hours (Fig. 5-2). The anabolites became detectable mostly within 17 min 
after 5-FU administration and were increasing until they reached a plateau level 
during the first hour. The catabolites followed slightly later, after 25-34 min post 5- 
FU, and reached a plateau at approximately 60-68 min. The aforementioned time 
points were not shifted by carbogen with the exception of the catabolites which 
reached a plateau at 76-85 min. Two groups of mice treated with 5-FU alone (n = 
6) or plus carbogen breathing (n = 5) were compared. The maximum peak area 
(Cmax) of anabolites, 5-FU and total fluorine containing compounds was significantly 
higher after treatment with carbogen (Table 5-1). The AUC of A, C, F and T was 
also higher after treatment with carbogen, and showed a tendency for significance. 
The median t1/2 of 5-FU retention in the tumour after treatment with 5-FU alone and 
after addition of carbogen breathing was not different in both cases.
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Table 5-1 Effect of carbogen breathing on 5-FU pharmacodynamics in the C38 murine colon
19tumour obtained from in vivo F NMR spectra
Treatment Cmax of metabolites in arbitrary unitsa
5-FU A C F T=A+F+C
- carbogen median 
(range)
0.23
(0.13-0.53)
0.41
(0-0.66)
0.66
(0.23-1.58)
0.77
(0.50-1.74)
+ carbogen median 
(range)
0.47
(0.31-0.82)
0.92
(0.33-2.41)
1.41
(1.23-2.41)
1.46
(1.23-3.56)
P value P = 0.03 P = 0.08 P = 0.01 P = 0.01
Treatment AUC of metabolites in arbitrary unitsb
5-FU A C F T=A+F+C
- carbogen 16
(3-33)
16
(0-28)
31
(11-66)
53
(32-115)
+ carbogen 26
(17-33)
32
(15-142)
43
(39-100)
101
(71-269)
P value P = 0.11 P = 0.05 P = 0.06 P = 0.04
T reatment t1/2 of 5-FU (min) c
5-FU F
- carbogen 34.0
(17.0-34.0)
+ carbogen 34
(25.5-42.5)
P value P = 0.40
a Cmax is the maximum peak area (by block of 8.5 min) given in normalised values, which are 
achieved by dividing integrals by the mean integral of the 1H spectra and multiplying by 1000; 
b AUC is area under the concentration-time curve (from 0 to 119 min) also in normalised values 
of anabolites (A), catabolites (C), 5-FU (F) and total fluorine-containing compounds (T); 
c t-|/2 is half-life of 5-FU (after Cmax) in the tumour after treatment with 5-FU 150 mg/kg 
alone (n = 6) or together with carbogen breathing (n = 5).
5-FU, 5-fluorouracil; NMR, nuclear magnetic resonance.
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Fig. 5-2. Effect of carbogen breathing on time dependence of 5-FU metabolite pattern in 
the C38 murine colon tumour. Data are normalised values of the integrals of the signals 
of anabolites (A), catabolites (C), 5-FU (F) and total fluorine-containing compounds (T) 0­
119 min after 5-FU injection. Points, mean values of 5-6 mice. (A) Treated with 5-FU 
alone; and (B) treated with 5-FU plus carbogen breathing during the first 8.5 min. Data 
time points represent the end of data accumulation periods, e.g. 8.5 min stands for a 
spectrum collected from 0 to 8.5 min.
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Histological characterisation and perfusion of tumours
Histological examination of six separate tumours of comparable weight was perfor­
med. The tumours consisted of a poorly differentiated adenocarcinoma which 
contained 15-30% necrosis.
One of the most important parameters for tumour vascularisation and perfusion is 
the perfusion fraction (PF), indicating the fraction of vessel structures that are perfu­
sed. The median PF was relatively high: 0.83 (range 0.72-0.97). A high PF means 
that the tumour is well perfused. Images of immunohistochemical stained sections 
showed that the tumour was also well and regularly vascularised.
Effect of carbogen breathing on tumour growth and body weight
The tumour weight was 0.4-0.8 g. No difference in tumour growth behaviour was 
seen for the two treatment groups in this experiment. The minimal tumour volume 
after treatment (relative mean 0.40 and 0.33) and the tumour volume 14 days after 
treatment (1.88 and 2.93) were not significantly different for the groups treated 
resp. without and with carbogen, as well as the doubling time after the minimal 
tumour volume (4.34 and 3.14 days).
The mean maximal loss of body weight in 14 days after treatment was 7 + 4% 
standard deviation (S.D.) for the group treated with 5-FU alone and 11 + 9% for the 
group treated with 5-FU plus carbogen. This parameter was taken as an indicator 
for the maximal tolerated dose. In this period there was one toxic death in the group 
treated with 5-FU alone.
Discussion
According to Presant and colleagues an increased 5-FU uptake in the tumour, an 
improved metabolism to anabolites and a higher t1/2 of 5-FU retention are predictive 
for a better response to therapy [22]. Carbogen breathing can cause vasodilatation 
and increased perfusion and is a potential method to improve the effect of
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chemotherapy [12]. The purpose of this study was to answer the question of 
whether carbogen breathing increases the uptake, retention and metabolism of 5- 
FU in a murine colon tumour and thus results in an enhanced tumour growth delay. 
We have found that carbogen breathing indeed increased tumour levels of 5-FU 
and its metabolites. In addition to vasodilatation and increased perfusion the drop in 
extracellular pH compared with the intracellular pH after carbogen breathing may 
have contributed to the increased cellular uptake of 5-FU [13,14]. Carbogen and 
nicotinamide can act on both diffusion-limited hypoxia and intermittent perfusion- 
limited hypoxia [23]. Alone and in combination they can decrease the number of 
mismatched and closed vessels, but this is dependent on tumour type.
However, the present study did not reveal an effect of carbogen breathing on tu­
mour growth delay by 5-FU, despite the higher 5-FU and 5-FU metabolite levels 
attained with carbogen breathing. In addition, no enhancing effect of carbogen on 
5-FU retention in the tumour was found. Several reasons may explain the lack of 
effect of carbogen on tumour growth inhibition notwithstanding increased 5-FU and 
5-FU metabolite levels. One reason could be that in the C38 tumour the uptake of 
5-FU and its immediate conversion are not rate limiting in the effect of 5-FU on 
tumour growth inhibition and that the tumour was already responding effectively to 
this treatment. Supporting this hypothesis is the high t1/2 of 5-FU retention without 
(median 34 min, range 17-34 min) and with carbogen (median 34 min, range 25.5­
42.5 min), whereas a t1/2 of less than 20 min is found in other tumours [13,24]. It is 
possible that because carbogen did not increase this t1/2 further, no additional effect 
on tumour growth inhibition was seen.
The particular reason for the lack of effect of carbogen on tumour growth inhibition 
is unclear, but could be related to some tumour characteristics such as tumour type 
and size [12]. In addition, the combination with other treatment strategies, such as 
multiple dosing, may be more effective. Differences in vascularisation may play an 
important role in differential effects. Recently, the effect of carbogen breathing on 5- 
FU uptake and cytotoxicity was studied by others in hypoxic murine RIF-1 tumours,
19also using F NMR spectroscopy [13].
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In conclusion, this study showed increased levels of 5-FU and its anabolites and 
catabolites after carbogen breathing. This indicates that carbogen could be of 
importance to improve the uptake and metabolism of 5-FU in colorectal cancer. 
However, no effect of carbogen breathing on tumour growth inhibition was obser­
ved, possibly due to the small size and well perfused condition of the tumour.
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Abstract
5-Fluorouracil (5-FU) was studied in two variants of a murine colon carcinoma, 
the C26-B which is relatively insensitive, and the C26-10 which is sensitive to 5- 
FU. These two tumour variants were compared with respect to 5-FU uptake,
19retention and metabolism using F magnetic resonance spectroscopy (MRS) in 
vivo, the level of the target enzyme thymidylate synthase (TS), 5-FU 
incorporation into RNA and tumour growth. In addition, the effect of carbogen 
breathing on 5-FU treatment was tested in these tumour models. Eleven C26-B 
and 15 C26-10 tumour-bearing mice were treated with 150 mg/kg of 5-FU given
i.p., whereas 11 C26-B and 9 C26-10 tumour-bearing mice received 5-FU while 
breathing carbogen gas (95% O2 and 5% CO2). The C26-10 tumour showed a 
significantly increased conversion of 5-FU to 5-FU anabolites, which are 
responsible for the cytotoxic effect of 5-FU, compared to the C26-B tumour. This 
result is reflected in a significantly larger tumour growth inhibition of the C26-10 
tumour compared to C26-B. The addition of carbogen breathing to 5-FU
19treatment did not significantly affect 5-FU metabolism as seen by F MRS, but 
appeared to inhibit growth in the C26-10 tumour. The activity of TS was 
significantly lower in the sensitive C26-10 tumours, while the inhibition of TS 
after 5-FU administration was retained longer in this tumour than in C26-B. The 
increased sensitivity of C26-10 seems to be related to both an increased 
accumulation of active 5-FU metabolites and increased inhibition of the target 
enzyme TS.
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Introduction
Colorectal cancer is the third most common cancer in the western world. The 
main cytostatic agent to treat this disease is still 5-FU, but it is only effective in a 
small percentage of patients. Insight in the behaviour of 5-FU in the body could 
learn us why certain patients do and others do not respond to treatment and how 
this therapy could be improved.
Whether 5-FU treatment will be effective is dependent on several factors, such 
as the uptake of 5-FU by the tumour and its metabolism in the tumour. Both
19aspects may be a function of tumour type and size. F MRS is a powerful 
method to asses these aspects in vivo.
19Monitoring the uptake and metabolism of 5-FU in solid tumours by in vivo F MRS 
has been described in a number of animal models. In 1984 Stevens and 
colleagues investigated the metabolism of 5-FU in implanted Lewis lung
19carcinomas by F MRS [1]. In spectra of this tumour a 5-FU and one anabolite or
fluoronucleotide (FNuct) peak were seen. In spectra of the CD8F1 murine
mammary tumour signals from 5-FU, FNuct, and the catabolites a-fluoro-G-urei-
dopropionic acid (FUPA) and a-fluoro-R-alanine (FBAL) were observed after 5-
FU administration [2]. Formation of FNuct was increased with MTX pre-treatment.
In the rat Walker carcinosarcoma tumour growth inhibition correlated with the dose
of 5-FU and the level of FNuct [3]. MTX pre-treatment increased the level of FNuct
formation resulting in increased growth delay. In RIF-1 tumours the FNuct level and
the 5-FU induced decrease in tumour volume showed a significant correlation [4].
The purpose of the present study was to examine the uptake and metabolism of
5-FU in two variants of a murine colon carcinoma with a different sensitivity to 5­
19FU, using F MRS, in relation to their growth in vivo. Tumour models of colon 
carcinoma have not been investigated yet in this way and a study of different 
sensitivity to 5-FU is clinically relevant, as in patients with this tumour type a 
wide range of 5-FU sensitivity is encountered. In addition, we have examined the
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effect of carbogen breathing on the efficacy of 5-FU treatment in these two 
tumour variants. Carbogen breathing may cause vasodilatation and increased 
perfusion and thus enhanced delivery of 5-FU. The question was if carbogen 
breathing would increase the uptake, retention and metabolism of 5-FU in one or 
both tumour variants and if this would result in an enhanced tumour growth 
delay. Such a positive effect of carbogen on 5-FU pharmacokinetics has been 
observed in other tumours [5]. In a former study of another murine colon tumour 
we have found increased tumour levels of 5-FU and its metabolites as a result of 
carbogen breathing [6].
Materials and methods
Chemicals
5-FU was obtained from Teva (Mijdrecht, the Netherlands) as a saline solution at 
50 mg/ml. Carbogen gas (95% O2-5% CO2) was obtained from Hoekloos 
(Schiedam, the Netherlands).
Tumour model
Female Balb/C mice of 8-12 weeks of age were obtained from the Central 
Animal Laboratory of our university. We studied two different variants of the C26 
murine colon carcinoma: the C26-B, relative insensitive to 5-FU, and the C26- 
10, sensitive to 5-FU [7]. Tumour tissue fragments with a diameter of 3 mm were 
implanted s.c. in the right flank of the mouse. Twelve days after implantation the 
C26-B tumours had then reached a weight of 0.68 (mean) + 0.49 g (SD) and the 
C26-10 tumours of 0.58 + 0.29 g after an average of 11 days. The tumour 
volume was estimated from three orthogonal diameter measurements using the 
following formula: tumour volume (mm ) = X x Y x Z x 0.5 [8]. Mice were divided 
into groups based on estimated tumour volume and stratified randomisation was
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carried out over the different treatment groups. The experimental procedures 
were approved by the local ethics committee for the use of animals.
Tumour growth
Mice were followed for tumour volume and body weight after the MRS experi­
ments. Those two parameters were determined twice a week for a period of 4 
weeks. Tumour volumes were normalized to 1 at day 0, which was the day of 
treatment. Antitumour activity was evaluated by analysing the area under the 
curve (AUC) of the growth curves; the tumour doubling time (TD), representing 
the time in which the tumours double their size after the start of treatment; the 
growth-delay factor (GDF = [TD treated mice - TD untreated mice]/TD untreated 
mice), which indicated the gain of doubling time by treatment; and the ratio of 
mean tumour volume of treated and untreated mice (T/C) [7]. The TD for 
untreated C26-10 and C26-B tumours was 4.1 and 2.9 days, respectively [7]. 
These TD-values are very consistent and were used as control for untreated 
mice. Toxic side effects were evaluated by weight loss. At the end of the experi­
ment the mice were sacrified.
Treatment
At the time of the experiment the tumour-bearing mice were canulated i.p. under 
inhalation anaesthesia using a mixture of enflurane (1.5%), oxygen (29.5%) and 
nitrous oxide (69%). The temperature of the mice was maintained at 37 0C. 5-FU 
was administered as a bolus i.p. at a dose of 150 mg/kg in normal saline (0.1 
ml/g) within 20 s. A group of C26-B (n = 11) and C26-10 (n = 15) tumour-bearing 
mice was treated in this way.
The same procedure was applied to another group of C26-B (n = 11) and C26- 
10 (n = 9) tumour-bearing mice but combined with carbogen breathing. After 
shimming, carbogen (2 l/min) was switched on for 9.5 min, whilst turning off the 
nitrous oxide and oxygen. After the first minute of carbogen breathing 5-FU was 
administered.
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19F MR spectroscopy
19F MR spectra were measured at 169.457 MHz on a 4.3 Tesla (T) Oxford
1 19vertical bore magnet equipped with a SMIS console. A home-built H/ F double 
tuneable radiofrequency (RF) coil with an internal diameter of 13 mm and two 
windings was placed around the tumour. Shimming was performed until a H2O
19signal line width at half-height of less then 70 Hz was obtained. F MR data
acquisition parameters were: spectral width 10 KHz, repetition time 0.5 s, flip
0 1  angle 90 with a rectangular RF pulse of 20 |js. No H decoupling was used.
Spectra were recorded from the moment of 5-FU injection. Measurements took
place during 2 h in blocks of 8.5 min (1024 acquisitions).
Before and after this session a H MR spectrum at 180.130 MHz was recorded
19by the F coil for normalisation using the signal of H2O as an internal reference. 
Sixty-four scans were recorded with a repetition time of 1 s. Because the H MR 
spectra were recorded before and 2 h after switching off the carbogen breathing, 
the influence of carbogen breathing on the relaxation of the H spins of water 
was excluded.
19Analysis of F MR spectra
19The F MR resonance frequency of 5-FU was set to a chemical shift value of 0 
parts per million (ppm). The integral for the signals of 5-FU (F), the FU anaboli- 
tes (A), and the FU catabolites (C) (FUPA and FBAL) was determined. Signals
19 1in F and H MR spectra were quantified by iterative fitting of the time domain 
signal using the software package MRU I [9]. All the peak areas were obtained 
by fitting the spectral lines to Lorentzian line shapes. The catabolite content was
19determined as the sum of the FUPA and FBAL signal intensities. All F curves 
were normalised by dividing the integrals by the mean integral of the H2O signal 
in the two H spectra. This assumes that the amount of hydrogen measured 
reflects the amount of measured tumour tissue, taking into account that a 
constant part of the tumour (85-90%) consists of water. By this semi-quantitative 
method it is possible to compare metabolite levels between the different groups.
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Analysis of 5-fluoro-2'-deoxyuridine-5'-monophosphate (FdUMP) 
concentration, 5-FU tissue levels and 5-FU incorporation into RNA
Tumours of a separate group of mice of each tumour group (C26-B and C26-10) 
were removed at different time points after treatment, and frozen in liquid nitrogen. 
Before analysis, frozen tumours were pulverised [10] and suspended at 1 volume 
tissue and 3 volumes appropriate assay buffer. This suspension was immediately 
prepared for the FdUMP and 5-FU assay. Tissues were extracted with 
trichloroacetic acid for assay of 5-FU and FdUMP; the acid-insoluble precipitate 
was used for isolation of RNA and measurement of 5-FU incorporation into RNA. 
FdUMP concentrations were measured as previously described [11] by means of a 
dilution assay based on the capacity of FdUMP present in the tumours to inhibit the 
binding of labelled FdUMP to L. casei thymidylate synthase. 5-FU tissue levels 
were measured as described previously [12]. Incorporation into RNA was 
performed in RNA isolated from the first precipitation step, as already described 
[13]: the assay is based on the degradation of RNA containing 5-fluorouridine-5'- 
monophosphate (FUMP) to 5-FU by incubation with RNAse and alkaline 
phosphatase and uridine phosphorylase. 5-FU was then extracted, derivatized and 
measured by gas-chromatography coupled to mass-spectrometry [13].
Evaluation of TS inhibition
Two assays were used for the evaluation of TS levels in tumours from drug- 
treated mice [11,14]. The ligand-binding assay of [6- H]FdUMP to TS gives an 
indication of the number of free binding sites of TS for FdUMP after treatment. In 
the TS catalytic activity assay, the conversion of [5- H] dUMP into dTMP and 
H2O is measured. TS was measured immediately after preparation of the 
extracts essentially as described elsewhere [11]. Tumours from untreated mice 
served as references.
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Statistics
Differences between the two MRS-groups, between enzyme activity and 
between tumour volume of treated/untreated mice (T/C) were analysed by the 
unpaired Student's f-test. For the MRS-parameters under maximum concentrati­
on (Cmax), tests were performed after log transformation, because of oblique 
distribution. For the MRS-parameters under area under the curve (AUC), tests 
were performed after root transformation. A two-sided significance level of 0.05 
was used. For the half-life (t1/2) of 5-FU and for the tumour doubling time (TD) 
the Wilcoxon 2-sample test was used. The growth curves of the mice after 
treatment were analysed by distribution-free analysis of variance on repeated 
measurements.
Results
19Comparison of in vivo F MR spectra of 2 different variants of C26 colon 
tumour
19In F MR spectra of mouse tumours treated with 5-FU, signals from 5-FU and 
from its anabolites and catabolites could be observed (Fig. 6-1). The 5-FU peak 
(F) was detected within the first 17 min after its administration and was 
decreasing thereafter. The anabolites of 5-FU occurred as one single peak (A), 
which started to show up during the second or third measurement block (8.5 -
25.5 min) after 5-FU administration, and were increasing until they reached a 
plateau phase. The catabolites were often present as two different peaks, the 
first peak (C between -16.5 and -17 ppm) representing FUPA and the second (C 
between -18 and -18.5 ppm) representing FBAL. Fig. 6-1^  shows typical in vivo 
spectra of a C26-B tumour and Fig. 6-1B of a C26-10 tumour. In the latter 
spectra the anabolite peaks are higher.
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Fig. 6-1.19F magnetic resonance (MR) spectra of A, C26-B and B, C26-10 murine colon 
tumour. Shown are sequential spectra at 17 min intervals (two spectra of 8.5 min 
summed) after i.p. injection of 150 mg/kg 5-FU. Plotted beside each spectrum is the time 
in min of the acquisition interval after injection of 5-FU. A, anabolites; C, catabolites; F, 5- 
FU.
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Table 6-1 Maximum peak area (Cmax by block of 8.5 min) and area under the concentration­
time curve (AUC from 0-119 min) of anabolites (A), catabolites (C), and 5-FU (F), 
and half-life (t1/2) of 5-FU in the tumour in C26-B and C26-10 murine colon tumours 
after treatment with 5-FU 150 mg/kg alone (n = 11 C26-B and 15 C26-10 tumours) 
or together with carbogen breathing (n = 11 C26-B and 9 C26-10 tumours)
Cmax of metabolitesa AUC of metabolitesb
Tumour Treatment
5-FU 5-FU
+carbogen
Treatment
5-FU 5-FU
+carbogen
C26-B
C26-10
P valuec
A 0.35 (0, 0.59) 
0.65 (0.31, 2.81) 
P = 0.0004
0.36 (0.21, 0.50) 
0.59 (0.45, 2.07)
A 20 (0, 34)
50 (20, 190) 
P = 0.0001
25 (9, 35)
48 (33, 139)
C26-B 
C26-10 
P value
C 0.51 (0, 3.58) 
0.35 (0, 3.56) 
P = 0.23
0.36 (0, 0.76) 
0.32 (0, 0.57)
C 17 (0, 129) 
13 (0, 96) 
P = 0.36
14 (0, 31) 
11 (0, 24)
C26-B 
C26-10 
P value
F 0.98 (0.44, 3.01) 
0.78 (0.38, 2.95) 
P = 0.82
0.78 (0.51, 1.61) 
1 (0.45, 2.07)
F 39 (15, 72) 
27 (11, 80) 
P = 0.63
34 (13, 77) 
38 (17, 85)
t1/2 of 5-FU (min)
C26-B Fd 25.5 (17, 51) 25.5 (8.5, 51)
C26-10 25.5 (8.5, 42.5) 34 (25.5, 34)
P value P = 0.51
a Data are medians and (minimum, maximum) in arbitrary units, where Cmax is the maximum 
peak area (by block of 8.5 min) given in normalised values, which are achieved by dividing 
integrals by the mean integral of the 1H spectra and multiplying by 1000. 
b AUC is area under the concentration-time curve (from 0 to 119 min) also in normalised 
values of anabolites (A), catabolites (C), and 5-FU (F). 
c Two-fold variant analysis is performed. P values are given for comparison of C26-B with 
C26-10 (-/+ carbogen) and not for comparison of treatment -/+ carbogen (C26-B/C26-10), 
because for the last comparison P values were never < 0.05. 
d t1/2 is half-life of 5-FU (after Cmax) in the tumour after treatment with 5-FU.
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The results of the experiment are presented in Table 6-1. Of the absolute 
parameters determined from the concentration-time curves, the Cmax and the 
AUC of anabolites were significantly higher for C26-10 than for C26-B. 
Treatment with carbogen had no significant effect on 5-FU metabolism in both 
tumour variants. No differences were found for levels of catabolites and 5-FU. 
Also the t1/2 of 5-FU retention in the tumour remained the same.
5-FU pharmacokinetic data and TS inhibition
The results of the enzyme assays and other parameters of 5-FU 
pharmacokinetics are presented in Table 6-2. FdUMP concentrations were 
higher in the C26-10 and its retention was longer. The incorporation of 5-FU into 
RNA was lower in C26-10 compared to C26-B. The 5-FU concentrations, 
measured after 7 and 10 days, were higher in the C26-10 tumours. The TS 
catalytic activity was lower in C26-10 in untreated tumours. After an initial 
decrease shortly after 5-FU administration the TS activity increased on day 7 
and returned on day 10 partially to control levels. The level of FdUMP binding 
sites was lower in C26-10 compared to C26-B tumours. In both tumours the 
decrease of FdUMP binding was followed by an increase on day 7 and a 
decrease on day 10.
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Table 6-2 5-FU pharmacokinetics and inhibition of TS
in C26-B and C26-10 tumours
Parameter Time C26-B C26-10 P <
FdUMP 2 h 13S i  30 179 i  42
(pmol/g w.w.) 4 h 107 i  22 147 i  7S
24 h 22.0 i  2.7 32 i  15
48 h 13.3 i  1.S 46 i  35
FU-RNA 2 d 7.41 i  0.30 2.25 i  1.55 0.01
(pmol/ug RNA) 3 d 6.63 i  0.20 1.71 i  0.53 0.001
7 d 0.25 i  0.25 0.40 i  0.01 0.001
10 d 0.06 i  0.01 0.16 i  0.01 0.001
5-FU 7 d 0.14 i  0.03 0.S2 i  0.34 0.05
(nmol/g w.w.) 10 d 0.12 i  0.02 0.79 i  0.22 0.02
TS catalytic activity Control 5.73 i  0.41 2.S5 i  0.20 0.001
(nmol/h/mg protein) 1 d 0.72 i  0.10 1.09 i  0.03 0.001
3 d 1.21 i  0.1S 1.72 i  0.4S
7 d 9.96 i  0.15 5.73 i  0.43 0.001
10 d S.55 i  1.24 1.92 i  0.2S 0.001
FdUMP binding Control 122 i  33 93 i  12
(fmol/g w.w.) 1 d 32.5 i  2.3 20.3 i  1.5 0.001
3 d 31.5 i  5.4 22.6 i  3.S 0.05
7 d 201 i  44 165 i  33
10 d 190 i  31 145 i  23
Values are means ± SD of 3-8 separate tumours. Differences between C26-B and 
C26-10 were evaluated using the Student's t test. P -values < 0.05 are mentioned.
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Difference in tumour histology
Histological examination of six separate tumours of both tumour variants was 
performed. Both tumours consisted of a poorly differentiated adenocarcinoma 
which contained less than 15% necrosis. There were no clear differences in 
histology between the two tumour variants.
Difference in tumour growth after 5-FU treatment
There was a difference between the growth curves of the mice with C26-B 
tumour and those with C26-10 tumour, either treated with 5-FU alone; or treated 
with 5-FU + carbogen (Fig. 6-2). Between the C26-10 tumours treated with 5-FU 
alone and those treated with 5-FU + carbogen also a significant difference was 
observed; but not between those with C26-B tumours treated with 5-FU alone 
and those treated with 5-FU + carbogen. After treatment with 5-FU +/- carbogen 
the C26-10 tumour growed less fast than the C26-B tumour. The T/C at day 7 
was lower for C26-B than for C26-10, treated with 5-FU +/- carbogen (Table 6­
3). Day 7 was the last day of measurement of the untreated C26-B control 
group. The TD of C26-B + 5-FU +/- carbogen were the same, and higher than 
for untreated controls. The TD of C26-10 + 5-FU was higher than for untreated 
controls, but lower than for C26-10 + 5-FU + carbogen. The TD of C26-10 + 5- 
FU was higher than the TD of C26-B + 5-FU and the TD of C26-10 + 5-FU + 
carbogen was higher than the TD of C26-B + 5-FU + carbogen. The GDF was 
comparable for C26-B + 5-FU +/- carbogen and for C26-10 + 5-FU, but higher 
for C26-10 + 5-FU + carbogen.
The mean weight loss per time point was maximally 6% in the group of mice with 
C26-B tumours treated with 5-FU alone and maximally 12% in the other three 
groups, which was within accepted limits.
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Fig. 6-2. Growth curves of C26-B and C26-10 murine colon tumours after treatment with 
5-FU 150 mg/kg alone (n = 9 C26-B and 11 C26-10 tumours) or together with carbogen 
breathing (n = 11 C26-B and 10 C26-10). The relative tumour volume on day 0 is fixed to 
1. Difference between growth curves of group 1 and 3 (P = 0.02); group 2 and 4 (P = 
0.003); group 3 and 4 (P = 0.03); group 1 and 2 (P = 0.35).
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Table 6-3 Antitumour activity of 5-FU +/- carbogen breathing 
in C26-B and C26-10 murine colon tumours
Tumour Treatment n
(TD)
TDa
(days)
GDFb T/Cc 
(day 7)
n d 
(WL)
WLe
(%)
C26-B - 2.9
(1) 5-FU 9 10.20 (6.94, 17.08)f 2.52 0.16 + 0.07 10 5.6
(2) 5-FU + carbogen 11 10.21 (6.94, 19.55)f 2.52 0.15 + 0.05 11 11.1
C26-10 - 4.1
(3) 5-FU 11 13.26 (9.34, >29)f 2.23 0.35 + 0.11g 13 11.9
(4) 5-FU + carbogen 10 >28 (9, >29)f >5.83 0.36 + 0.13g 10 11.1
a Data are medians (minimum, maximum).
For untreated C26-B and C26-10 tumours a historical control was taken of 2.9 resp. 4.1 days.
After 28-29 days, at the end of the experiment, some tumours doubled not their initial volume (>).
In 1 C26-10 tumour treated with 5-FU and in 1 C26-10 tumour treated with 5-FU + carbogen 
a complete response was reached. 
b GDF > 2, sensitive.
c T/C at last day of measurement of C26-B control group. Data are means + SD. 
d For weight loss all mice were calculated, also those with < 3 observations (total 3 mice). 
e Mean weight loss per time point was maximally 12 %. 
f (1) vs (2) P = 0.62; (3) vs (4) P = 0.033;
(1) vs (3) P = 0.048; (2) vs (4) P = 0.002, Wilcoxon 2-sample test. 
g (1) vs (3) P = 0.0001; (2) vs (4) P = 0.0003, Student's t -test.
Discussion
19F MRS detection of the uptake, retention and metabolism of 5-FU by tumours 
in vivo has been described in a number of animal models including colon 
carcinoma e.g. the C38 colon carcinoma [15], but not in the C26 murine colon 
carcinoma. We have performed a study of variants of this model with a different
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sensitivity to 5-FU, reflecting the situation in patients. The relative insensitive 
C26-B tumours are characterised by having higher basal TS catalytic activity 
compared to 5-FU sensitive C26-10 tumours [7]. TS catalyses a critical step in 
the pathway of DNA synthesis and forms a target for chemotherapeutic agents 
like 5-FU [16]. FdUMP, a metabolite of 5-FU and an analogue of dUMP, acts as 
a TS inhibitor. FdUMP blocks the de novo dTMP production by the formation of 
a stable ternary complex between FdUMP, the co-factor folate and TS. The 
effect of TS inhibition is a depletion of dTMP and subsequently dTTP, which is 
normally incorporated in DNA. The higher TS activity of C26-B could explain its 
lower sensitivity for 5-FU.
19In our study of the C26-B and the C26-10 tumour we have observed by F MRS 
a difference in 5-FU metabolism between the two tumour types. The C26-10 
tumour shows an increased conversion of 5-FU to 5-FU anabolites compared to 
the C26-B tumour. These results emphasise the notion that the level of 
anabolites is the most important parameter for response to treatment [3] and 
indicate that the metabolism on itself is an important factor that influences the 
therapeutic outcome. An explanation for the enhanced anabolite level in C26-10 
compared to C26-B can be that in C26-10 more 5-fluorouridine 5'-triphosphate 
(FUTP) is formed due to a low dihydropyrimidine dehydrogenase (DPD) level 
which causes a longer half life of 5-FU. However, DPD was not measurable in 
these tumours [17]. The catabolites are probably originating from normal tissue, 
especially liver [18]. Another explanation can be a higher activity of uridine 
phosphorylase or uridine kinase by which more FUMP is formed and 
subsequently FUTP and 5-fluoro-2'-deoxyuridine-5'-triphosphate (FdUTP). FUTP 
is incorporated into RNA and FdUTP into DNA. These mis-incorporations cause 
RNA and DNA damage and subsequent cell death. However, Holland et al. 
found an indication that uridine phosphorylase probably not does play an 
important role in the anabolism of 5-FU [15]. They found in the C38 murine colon 
tumour a higher 5-fluorouridine (FUrd) accumulation when uridine 
phosphorylase was inhibited by benzyl acyclo uridine (BAU). In that case 5-FU
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should be converted to FUMP directly and subsequently degraded to FUrd. This 
futile cycle forms a 5-FU deposit that leads to a longer retention of 5-FU in the 
tumour. Another way of 5-FU deposit is incorporation into RNA. After breakdown 
of RNA, because of fast turn-over of (tumour) cells, 5-FU will become available 
again for synthesis of FdUMP and inhibition of TS. 5-FU is measurable in RNA 
at least 10 days after treatment (Table 6-2). Furthermore, the pools of reduced 
folates are higher in C26-10 than in C26-B, resulting in a better TS-inhibition
19[19]. Important for the interpretation of F MRS studies is that FUTP is formed at 
intracellular concentrations up to 50 times those of FdUMP [20,21], whereas the 
concentrations of free FdUMP is < 1 |j.M and of the ternary complex even lower 
[22], hampering 19F MRS detection of FdUMP. Although FdUMP was not
19measurable by F MRS, its concentration was high enough in these tumours 
[11,14] and in patients [12] to inhibit TS effectively.
The growth curves of C26-B and C26-10 tumours are different, but not the 
antitumour effect, except in the C26-10 group treated with 5-FU + carbogen. The 
C26-B is known to be less sensitive to 5-FU at weekly doses of 100 mg/kg [7]. 
Possibly because of the higher dose (150 mg/kg), the T/C at day 7 (last day of 
measurement of untreated C26-B control group) is lower for C26-B than for C26- 
10. 5-FU effect is dose dependent [23]. Compared with the other 3 groups the 
C26-10 group treated with 5-FU + carbogen has a higher TD, a higher GDF and 
a flatter growth curve.
Carbogen breathing does not significantly affect 5-FU metabolism as seen by
19F MRS, although it inhibits growth in the C26-10 tumour. Carbogen breathing 
can cause vasodilatation and increased perfusion and is possibly a method to 
improve the effect of chemotherapy. In this study in the C26-B and C26-10 
tumours no significant effect of the carbogen breathing procedure on 5-FU
19pharmacokinetics was found by F MRS. Effect of carbogen may be dependent 
on tumour characteristics such as tumour type and size [24]. In addition in 
normal tissues carbogen breathing did not affect 5-FU deposition [25].
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Vascularisation, perfusion and pH of tumours play an important role in the 
response to cytotoxic agents [25].
19In conclusion this study using F MR spectroscopy shows increased levels of 5- 
FU anabolites for the 5-FU sensitive C26-10 tumour compared to the C26-B 
tumour, which is relatively insensitive to 5-FU. This is reflected in a less fast 
tumour growth of C26-10 compared to C26-B. All pharmacodynamic parameters 
important for cytotoxicity of 5-FU are in favour of C26-10, except RNA 
incorporation. Apparently in the present tumour model the 5-FU incorporation into 
RNA does not play an important role in the antitumour activity of 5-FU. In line with 
this is the observation that in some tumours modulation of 5-FU incorporation into 
RNA did not affect the antitumour activity [23]. In addition it was found that 5-FU 
plus carbogen breathing did not influence significantly the 5-FU metabolism, but 
inhibits growth in the C26-10 tumour.
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Abstract
The purpose of this study was to examine uptake and metabolism of 5-FU in 
liver metastases of human colorectal cancer as well as vascularisation of 
metastases. Patients with liver metastases of colorectal cancer were treated 
weekly with 5-fluorouracil (5-FU) (500/600 mg/m ) + folinic acid + trimetrexate.
19They were investigated with F MR spectroscopy (MRS, n = 17) and dynamic 
contrast-enhanced MR imaging (dMRI, n = 28). These investigations were 
performed in a random group of patients with liver metastases of colorectal 
cancer, not selected for the presence of very large metastases. MR spectra of all 
17 patients showed 5-FU and catabolite resonances and spectra of 7 patients 
also revealed resonances of fluoronucleotides. Correlations were found between
19F MRS parameters (volume of metastases in the field of the coil, t1/2 of 5-FU, 
Cmax of catabolites) and response. In these 17 patients plus 11 additional 
patients dMRI was performed and the onset of contrast-enhancement of liver 
metastases was determined. Liver metastases showed increased contrast 
uptake, indicating high vascularisation, but the onset of contrast-enhancement
19did not correlate with response. In conclusion, correlations of F MRS 
parameters with treatment response were found, especially in the group with 
larger metastases (Cmax of catabolites). However, this correlation was not 
observed in the group with smaller metastases, probably because of significant 
contribution of normal liver tissue to the MR spectra.
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Introduction
5-Fluorouracil or 5-FU is still the most important cytotoxic agent in the treatment of 
colorectal cancer. It is also used in other gastro-intestinal malignancies and in 
cancer of the breast or head and neck. 5-FU is combined with different modulators 
in order to enhance effectiveness, of which folinic acid has proven to give a survival 
benefit. There may be three conditions of importance for tumour response to 5-FU 
[1]. First, adequate exposure of the tumour to 5-FU, requiring good tissue 
accessibility. This may be assessed by dynamic contrast-enhanced MR imaging 
(dMRI), using the extracellular contrast agent diethylenetriaminepentaacetic acid 
(Gd-DTPA) [2,3], as this is a method which is sensitive to blood flow, vascular 
permeability, vascular surface area and interstitial space [4,5]. Second, adequate 
uptake of 5-FU from the vascular space into the cellular (and interstitial) space of 
the tumour. A non-invasive method to measure the presence of 5-FU in the tumour
19is F MR spectroscopy (MRS) [6,7]. Third, favourable biochemical characteristics
19of the tumour cell. This can also be assessed by F MRS next to the determination
19of cellular parameters such as thymidylate synthase activity. In this study F MRS 
was combined with dMRI to get information about 5-FU uptake and metabolism as 
well as the role of vascularisation in patients with liver metastases of colorectal
19cancer. One of the limitations of F MRS, but less of dMRI, is spatial resolution. 
The hypothesis of this study was that these two types of MR investigations could 
give complementary information. The results can be compared with the outcome of 
the radiological response evaluation.
19Only a few groups have performed F MRS studies of 5-FU in patients. Wolf 
and Presant and colleagues were able to detect 5-FU, but none of its metabolites, 
in several tumours of patients with different types of cancer [8,9]. The half-life (t1/2) 
of 5-FU in tumours was shown to be much longer (20 minutes or more) compared 
to the t1/2 of 5-FU in blood (8-12 minutes). The extent of trapping of 5-FU in tumours 
correlated with the anti-tumour response. Findlay et al. [10] found a correlation 
between a detectable 5-FU signal observed during the first 8 weeks of treatment
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and response to treatment with continuous low-dose intravenous infusion of 5-FU
19+/- a-interferon. The F MR spectra of some patients showed an anabolite signal. 
Schlemmer et al. [11] found a correlation between enhanced 5-FU levels in liver
19metastases and response. The same group also performed F MRS on cervical 
lymph node metastases of patients with head and neck carcinoma [12]. Patients 
were treated with simultaneous radiochemotherapy containing 5-FU. The levels of 
5-FU and its catabolite a-fluoro-G-alanine (FBAL) were higher at the second 
chemotherapy cycle compared with the first examination. No correlation between
19response to treatment and F MRS parameters was found. Li and colleagues [13]
19obtained localised F MR spectra of the liver of patients receiving 5-FU using
19three-dimensional chemical shift imaging. These studies show that F MRS could 
be a powerful technique to monitor the intratumoural metabolism of 5-FU in 
patients, and may be used to predict therapy outcome. dMRI with Gd-DTPA has 
been performed in the liver for imaging purposes of metastases [14]. As yet no
19studies of F MRS in combination with dMRI of the liver have been published.
Patients and methods 
Patients
Seventeen patients (2 female, 15 male) with colorectal cancer with liver
19metastases and no previous chemotherapy were studied with 19F MRS (MRS 
study). For patient characteristics see Table 7-1. Patients were eligible for this 
study if they had a measurable liver metastasis of at least 2 cm diameter in the 
field of the coil (within 8 cm of the skin surface) and were scheduled to receive 
5-FU containing chemotherapy as described below. Patients with claustrophobia
19were excluded. When they turned out to be too obese for the F MRS study (fat
stlayer > 3 cm on 1 MRI), only the dMRI study was performed. The mean age of 
the patients was 59 years (range 33 - 77 years).
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Table 7-1 Patient data (MRS group)
No. Age Sex Location
primary
tumour
Location 
meta 's
Vm in 
FOV
(cm3)
Vm/d2
(cm)
5-FU/TMTX
dose
(mg/m2)
A tumour 
size 
(%)
3 35 M rectum liver 9 0.18 600 68% (SD)
5 77 M colon liver 26 0.36 600 100% (SD)
6 53 M colon liver 6 0.31 600 30% (PR)
11 60 M rectum liver, lung, local recurrence 0.5 0 300 45% (PR)
14 62 M rectum liver 24 0.61 600 205% (PD)
15 75 M rectum liver, lung 19 0.23 600 143% (PD)
16 75 M colon liver 6 0.25 500/110 72% (SD)
17 45 M colon liver 4 0.11 450 54% (SD)
1 59 M colon liver, local recurrence 74 6.42 500/110 37% (PR)
2 65 M colon liver 179 9.69 600 86% (SD)
4 55 M colon liver, lymph nodes 72 8.56 500/110 100% (SD)
7 33 M colon liver 42 5.34 500 77% (SD)
8 72 M colon liver 50 3.88 600 100% (SD)
9 49 V rectum liver, lung 92 4.73 600 136% (PD)
10 73 M colon liver, lung 34 1.11 600 95% (SD)
12 56 V colon liver 24 0.65 450 149% (PD)
13 52 M colon liver, peritoneum 8 0.72 600 100% (SD)
19Abbreviations: Vm in FOV, volume of metastasis within field of view of F MR coil; 
d, distance to the coil; % tumour volume compared to pretreatment;
PR, partial response; SD stable disease; PD, progressive disease.
The sequence of patient no. is comparible with Table 7-2.
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Primary tumours were located in the colon (n = 12) or rectum (n = 5). Ten 
patients showed isolated liver metastases, 7 patients had also metastases in 
lung, lymph nodes, peritoneum or a local recurrence.
All 17 patients of the MRS study were also investigated in the MRI study, 
together with 11 additional patients (5 female, 23 male), who were studied only
19with dMRI and not with F MRS, mainly because they were too obese to fit into 
the MR apparatus on their stomach or right side with the liver on the coil in the 
table. The dMRI was intended to be performed before and after the first 
treatment cycle. Twenty of these 28 patients underwent both dMRI 
investigations, 6 patients only after treatment and 2 patients only before 
treatment because of early clinical progression. The mean age of the patients 
was 57 years (range 33 - 77 years). Primary tumours were located in the colon 
(n = 22) or rectum (n = 6). Eighteen patients showed isolated liver metastases, 
10 patients had also metastases in lung, lymph nodes, peritoneum or a local 
recurrence. The study was approved by the local ethical committee, and 
informed consent was obtained from all patients prior to the examinations.
Treatment
2 2  Patients were treated with 5-FU 600 mg/m + folinic acid 200 mg/m (MRS study,
n = 14; MRI study, n = 17) or 5-FU 500 mg/m2 + folinic acid 200 mg/m2 +
trimetrexate 110 mg/m (MRS study, n = 3; MRI study, n = 8). 5-FU was
administered as a short intravenous (i.v.) infusion within 5 min, preceded by
folinic acid in one hour and sometimes also by trimetrexate in one hour 24 hours
before 5-FU. Treatment was given weekly, 6 out of 8 weeks. In the MRI study 3
19patients, who where not eligible for the F MRS study, were treated with 5-FU
2 2  425 mg/m + folinic acid 20 mg/m 5 days every 4 weeks. Sometimes the dose
of 5-FU had to be reduced, because of toxicity. This happened three times in the
19F MRS study (Table 7-1) and five times in the MRI study.
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Assessment of response
Bidimensional measurement of tumour lesions was performed with conventional 
CT or ultrasound after each treatment cycle, within 8 weeks.
Radiological responses were classified according to the World Health 
Organisation/Southwest Oncology Group Criteria: complete remission (CR) for 
total disappearance of the tumour mass, partial remission (PR) for a decrease 
by at least 50%, stable disease (SD) for a change of tumour size between -50% 
and +25%, and progressive disease (PD) for an increase by at least 25% or new 
lesions. Furthermore, for this study the percentage change of the radiological 
response (A tumour size) after the first cycle of 5-FU therapy was determined.
19F MR spectroscopy
19F MRS was performed on a 1.5-T whole-body MR system (Vision, Siemens, 
Erlangen, Germany). A 1-turn RF surface coil of 10 cm loop diameter was
19employed both in transmit and receive mode at the frequencies for F 
(59.835712 MHz) and 1H (63.602815 MHz). A sample of trifluoroacetic acid 
(CF3COOH) fixed in the centre of the coil was used for calibrating chemical shifts 
5 (5 5-FU was set to 0 ppm) and as a 19F MR signal reference to account for 
different coil loading and to normalise peak integrals. CF3COOH resonates at
1993.6 ppm downfield from 5-FU. For F MR data acquisition an initial spectral 
width of 20 kHz was used to detect the reference signal and for the actual data a 
spectral width of 3500 Hz was used, zoomed in on the region with relevant 
signals. Spin excitation was performed with an adiabatic 900 pulse. A repetition 
time of 256 ms was used, which is somewhat arbitrary and difficult to set
19precisely at an optimum, as T1 values of F metabolite spins in vivo in patients 
are uncertain (between ~0.12 and 1.7 sec) [15,16]. Repetition times as short as
19 138 ms have been applied for in vivo F MRS [12]. No H decoupling was used. 
Data acquisition took place in blocks of 4 min (938 acquisitions) with a median 
total duration of 40 min (range 28-52 min) after the bolus injection. Patients were 
positioned on the surface coil in the table, lying on their stomach or right side.
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Gradient echo images were recorded to confirm that the sensitive volume of the 
surface coil covers a significant portion of the liver. The metastases in the liver 
were located as close as possible to the RF coil. Optimisation of magnetic field 
homogeneity (shimming) was performed on the tissue water H resonance. After
19switching to the F frequency, the 5-FU dose, dissolved in 40 - 50 ml isotonic 
saline, was administered within 5 min and MR spectra were acquired
stcontinuously. Patients were examined preferably during week 6 of the 1 
treatment cycle.
Dynamic contrast-enhanced MR imaging
Dynamic MRI was performed on the same 1.5-T whole-body MR system with 
use of a body phased array coil. Precontrast, a half Fourier turbo spin-echo T2 
sequence (HASTE, repetition time [TR] = 4.4 ms, echo time [TE] = 64 ms, matrix 
size 128 x 256) was made in the transversal and coronal planes. In addition, a 
fast low-angle shot T1 magnetisation-prepared sequence (FLASH 2D, flip angle 
800, TR = 125 ms, TE = 4.1 ms, matrix size 117 x 256) was acquired in the 
transversal plane. During bolus injection of 15 ml Gd-DTPA (Schering, Berlin, 
Germany) (dose 0.1 mmol/kg), using a contrast injector (Medrad, Pittsburgh, 
Pennsylvania), contrast uptake was monitored (FLASH 2D, TR 50 ms, TE = 4.4 
ms, matrix size 160 x 256, 7 slices, 44 images) with a temporal resolution of 2 
sec. This high temporal resolution sequence was used to enable accurate 
visualisation of differences in onset of contrast enhancement [17].
Data analysis
Spectral data were analysed on a SUN computer (Sun Microsystems, Palo Alto, 
California) using the software package MRUI [18], developed for quantitative
19evaluation of MR spectra. Detected F MR resonances were assigned on the 
basis of published chemical shift data [10,11]. 5-FU and FBAL resonances were 
analysed by means of a fit routine, assuming Lorentzian line shapes. The areas
19( F MR signal intensities) of the fitted lines were integrated and divided by the
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peak area of the reference CF3COOH. These normalised peak integrals were 
plotted as a function of time. The parameters Cmax and AUC define maximum 
signal intensity and area under the concentration-time curve and were 
determined graphically from the fitted curve. They were corrected for the 
administered 5-FU dose.
19The volume of the examined liver metastases (Vm) within the field of the F MR 
coil was approximated by an ellipsoidal shape: Vm = n/6 (dx x dy x dz), where dx, 
dy and dz are orthogonal diameters that are measured by means of MRI. The
3 3median of these tumour volumes was 24 cm (range 0.5 - 179 cm ). The local 
RF sensitivity of the surface coil is confined to a half-sphere (radius about 5 cm), 
with decreasing sensitivity at increasing axial distance (d) with respect to the
centre of the coil. Two groups of patients were distinguished: (a) Vm/d < 0.65
2 2  cm and (b) Vm/d > 0.65 cm. The median value of Vm/d of 0.65 cm divides the
19patients in 2 groups: (a) with a smaller contribution of the metastases to the F 
MRS signal and (b) with a larger contribution. In group (a) the contribution of the 
normal liver tissue to the signal is larger than in group (b). Schlemmer et al. also 
distinguished 2 groups of patients with comparable small (< 20 cm ) and large 
volumes of metastases (> 20 cm ) [11]. The median value of Vm in our MRS 
study (24 cm ) was comparable. In order to determine t1/2 of 5-FU, 5-FU peaks 
were fitted to a mono-exponential equation, y = A x e-kt.
Imaging data were analysed on a workstation (Hewlett Packard, Palo Alto, 
California). Subtraction and colour-coded time-images were calculated as 
described previously [19]. With the fast dynamic technique, the onset of 
contrast-enhancement of the liver metastases in relation to the start of aortic 
contrast-enhancement (t0) was determined. This parameter was selected, as it 
requires no particular calibration [17].
Statistics
19In Table 7-2 F MRS parameters were correlated with A tumour size (determined 
bidimensionally by CT or ultrasound) using Spearman correlation analysis. In Table
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7-3 dMRI parameters (t0 values) were correlated with A tumour size, also using 
Spearman correlation analysis. A correlation coefficient > 0.70 was considered to 
imply a good correlation.
Results
Response to treatment
Based on CT (14 times) or ultrasound (3 times), of the 17 patients studied with
1919F MRS (MRS study) 3 were classified as having a partial response, 10 having 
stable disease and 4 having progressive disease. Of the 28 patients studied with 
dMRI (MRI study) 5 had PR, 14 SD and 9 PD, based on CT (25 times) or 
ultrasound (3 times). The response rate was determined after the first evaluation 
after 2 months. No complete responses were observed at this time.
19F MR spectroscopy
19F MRS is a method to investigate the pharmacokinetics of fluorine-containing 
drugs like 5-FU [6,7] and its conversion into anabolites (fluoronucleotides and 
nucleosides) and catabolites (FBAL, a-fluoro-G-ureidopropionic acid [FUPA] and 
dihydrofluorouracil [DHFU]). It is assumed that the anabolic processes predominate 
inside tumour cells, whereas the catabolism takes place in the liver, but also in 
extrahepatic tissue [20-22]. By recirculation catabolites can enter tumour cells 
afterwards.
1919F MRS data acquisition was started 4 min before 5-FU administration in order 
to obtain a baseline spectrum with the reference signal. It was continued during 
5-FU administration (Fig. 7-1), and terminated after the 5-FU signal had
19disappeared, i.e. after a mean period of 42 + 7 (sd) min. F MR resonances for 
5-FU and FBAL were observed, with a chemical shift difference of 18.9 + 0.6 
(sd) ppm between both peaks.
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C
F
F time (min)
ppm 10 0 -10 -20 -30
Fig. 7-1. 19F MR spectra of the liver with metastases of a 5-FU treated patient. Shown 
are sequential spectra at 4 min intervals after 5-FU administration from 0-3 min.
A, anabolites; C, catabolites; F, 5-FU. Insert: A, F and C at 16-20 min.
FUPA resonates about 1.8 ppm downfield from FBAL, but was mostly not 
observed as a resolved peak. Also sporadically observed was the catabolite 
DHFU at about -32 ppm. Furthermore, in 7 out of 17 cases a fluoronucleotide 
signal could be seen at 4.9 + 0.5 (sd) ppm (Fig. 7-1). This peak was assigned to 
total 5-FU nucleosides and nucleotides. In the 19F MR spectra of the 17 patients, 
5-FU was detected immediately after the start of infusion (within 4-8 min); FBAL 
was detected later (mean 13 + 5 [sd] min) and was observed until the end of the 
examination in all cases except one; if fluoronucleotides were detected, they 
were seen during 4 min (one spectrum). Signal integrals of 5-FU and FBAL were 
obtained from spectral fits as described (see Patients and methods).
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4 8 12 16 20 24 
Time (min)
Fig. 7-2. Time courses of normalised peak integrals of 5-FU and FBAL of the same 
patient. •, Frel; O, Crel.
An example of time courses of the normalised peak integrals of 5-FU and FBAL 
is shown in Fig. 7-2.
In order to reveal differences in patients with metastases of varying sizes, two 
groups of patients were distinguished, with smaller and large volumes of 
metastases (see Table 7-2). The Cmax of 5-FU and FBAL was determined, as 
well as the AUC of the 5-FU curve, both divided by the dose of 5-FU.
19Furthermore the t1/2 of 5-FU washout was determined by F MRS. No increased 
retention of 5-FU was found in responding patients according to the t1/2 values. 
Actually, we never found an increased t1/2 of 5-FU compared to plasma, except 
once in a non-responding patient.
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Table 7-2 Patient data and 19F M RS results
Group (a) V m/d2 < 0.65 (n =8)
No. 5-FU Vm in Cmax AUC t1/2 Detection Cmax Atumour
dose FOV 5-FU 5-FU 5-FU 5-FU catabolites size
(mg/m2) (cm3) (min) (min) (% )
3 600 9 32 0.29 10 28 85 68% (SD )
5 600 26 92 1.72 12 44 160 100% (SD )
6 600 6 66 1.13 9 40 118 30% (PR )
11 300 0.5 53 0.43 4 12 63 45% (PR )
14 600 24 28 0.53 34 32 23 205% (PD )
15 600 19 57 1.10 11 44 98 143% (PD )
16 500 6 46 0.82 7 32 54 72% (SD )
17 450 4 67 0.94 7 32 91 54% (SD )
Median 600 7.72a 55 0.88
(LO9. 32 88
Group (b) V m/d2 > 0.65 (n =9)
No. 5-FU inmV Cmax AUC t1/2 Detection Cmax Atumour
dose FOV 5-FU 5-FU 5-FU 5-FU catabolites size
1 500 74 38 0.88 8 36 62 37% (PR )
2 600 179 55 0.81 6 28 93 86% (SD )
4 500 72 58 0.87 8 28 90 100% (SD )
7 500 42 68 1.01 10 32 52 77% (SD )
8 600 50 45 0.63 6 28 63 100% (SD )
9 600 92 68 0.99 7 32 120 136% (PD )
10 600 34 65 0.84 9 32 80 95% (SD )
12 450 24 78 0.88 8 20 184 149% (PD )
13 600 8 77 1.18 5 28 95 100% (SD )
Median 600 50.27 65 0.88 8 28 90a
a Spearman correlation coefficients between change in tumour size and 19F M RS results / 
patient data > 0.70.
Abbreviations other than in Table 7-1: Cmax, maximum peak area; AUC, area under 
the concentration-time curve; t1/2, half life.
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2In the patients with Vm/d < 0.65 cm (group a, n = 8) with a larger contribution of 
the normal liver tissue to the 19F MRS signal a high correlation was found 
between A tumour size and volume of metastases (in the field of the coil), and 
between A tumour size and t1/2 of 5-FU (Spearman correlation coefficient 0.79 
respectively 0.77). In the patients with Vm/d > 0.65 cm (group b, n = 9) with a
19larger contribution of the metastases to the F MRS signal a high correlation 
was found between A tumour size and Cmax of catabolites (Spearman correlation 
coefficient 0.81). The presence of a weak fluoronucleotide signal was seen in all 
3 patients with PR, but also in 2 patients with SD and even in 2 with PD and this 
does not correlate with A tumour size.
Dynamic contrast-enhanced MR imaging
Fig. 7-3A. Dynamic contrast-enhanced MR image of patients' liver with metastases. Onset 
of contrast uptake enhancement is colour coded: early (white-yellow-orange), late (blue). 
Liver metastasis (circle) shows a faster contrast uptake enhancement than surrounding liver 
tissue.
1, liver metastasis; 2, normal liver tissue; 3, right kidney; 4, left kidney; 5, spleen; 6, 
artefact of stomach movement; 7, enhancement band of aorta flow.
Fig. 7-3B. Spatial contribution of Gd-DTPA, 8 sec after onset of arterial contrast- 
enhancement, shows rim contrast-enhancement of the lesion (circle).
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Liver metastases showed a faster contrast uptake enhancement than the 
surrounding liver tissue, due to abnormal (neo)vascularisation (Fig. 7-3A). The 
spatial distribution of Gd-DTPA showed rim contrast-enhancement of the lesion 
(Fig. 7-3B). The onset of contrast-enhancement before (t0 before) and after (t0 after) 
treatment as well as its difference (At0) are given in Table 7-3. Mentioned is also 
tumour size after treatment, determined by CT or ultrasound. There was no 
correlation between A tumour size and t0 values (correlation coefficients < 0.70 and 
P  values > 0.10).
Table 7-3 Patient data and dMRI results (n = 28).
n min median max A tumour
sizea
Dose of 5-FU (mg/m2) 28 255 500 600
Tumour size after (cm2) 26 5 32 100
t0b before 22 2 6 14 -
t0 after 26 2 6 14 -
delta t0 20 -2 0 4 -
a Spearman correlation between change in tumour size and dMRI results. 
-, correlation coefficient < 0,70.
Abbreviation: t0 , onset of enhancement.
Discussion
Advanced colorectal cancer with liver metastases is a frequently occurring 
problem and treatment with cytostatics results only in a third of the patients in 
partial or complete response. In another third of the patients stable disease is 
achieved. It would be useful to have a method to predict in an early phase 
response to 5-FU containing therapy combined with modulators or other 
substances.
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19F MRS gives insight in the uptake and metabolism of 5-FU in tumours. In the 
spectra of all patients clear signals from 5-FU and FBAL were observed. 
Sometimes a small peak was seen at the position of the fluoronucleotides. Our 
results are comparable with those of Schlemmer and colleagues [11].
19In the group with a larger contribution of normal liver tissue to the F MRS signal 
(group a) there was a correlation between A tumour size (change determined 
bidimensionally by CT or ultrasound) and volume of metastases (in the field of the 
coil). This means that smaller tumours respond better, which is in congruence with 
clinical findings. Furthermore, there was a positive correlation between A tumour 
size and t1/2 of 5-FU, meaning that a longer t1/2 correlates with an increase in tumour 
size. This is the opposite of tumour trapping, where a long t1/2 in the tumour 
correlates with response to treatment (decrease in tumour size). In the group with a
19larger contribution of the metastases to the F MRS signal (group b), there was a 
correlation between A tumour size and Cmax of catabolites. This could mean that a 
higher degradation of 5-FU into catabolites correlates with a poorer response to 
treatment (increase in tumour size). Catabolites are thought to be produced in the 
normal liver and not in tumour tissue, where they appear by recirculation [23].
19Although some correlations of F MRS parameters with A tumour size were found, 
a useful and clear parameter for response to treatment was not discovered in this 
study. An explanation can be the volume of metastases in the field of the coil, 
which was sometimes very low (mean Vm = 24 cm ). Especially in group a (mean 
Vm = 8 cm3), but also in the group b (mean Vm = 50 cm3) with a larger contribution
19of the metastases to the F MRS signal, there was still a large contribution of 
normal liver tissue, because measurements were performed unlocalised. Patients 
with metastases with a minimal diameter of 2 cm in the sensitive field of the coil 
were included, which is small taking into account a coil diameter of 10 cm. 
Sometimes patients were not able to lie down in the ideal position and even a 
smaller part of metastases was adjacent to the coil. In those cases the major
19contribution to the F MRS signal is originating from the surrounding normal liver 
tissue. This is supported by the fact that often a considerable FBAL signal was
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measured, probably coming from the surrounding normal liver tissue. The spectral 
parameters Cmax and AUC, when analysed for patients with small volumes of 
metastases, mainly reflect processes in the normal liver tissue. In patients with 
large volumes of metastases within the field of the coil, signal from tumour tissue 
will contribute substantially to Cmax and AUC. This means that in a less selected
19group of patients F MRS results can differ from those in a group with very large 
metastases on the surface. Another explanation for the lack of finding a clear
19correlation of our parameters with response could be the timing of the F MRS 
study. 19F MRS was performed at the end of the 1st treatment cycle, i.e. at the 6th 
weekly 5-FU infusion. This is at the time of the radiographic evaluation. But after 5 
weeks of 5-FU treatment it is possible that we monitor the remaining resistant cell 
lines in all cases. To prevent this, 19F MRS performed earlier, i.e. at the 1st 5-FU 
infusion, would be preferable.
Dynamic contrast-enhanced MRI probes aspects of the vasculature of a tumour 
after administration of the extracellular contrast agent Gd-DTPA [2]. Differences in 
contrast uptake enhancement are expected between benign and malignant tissue, 
the last showing earlier contrast-enhancement due to abnormal 
(neo)vascularisation [3]. In this study no complete responses were achieved. This 
means that there will be still vital tumour tissue with neovascularisation and thus 
contrast-enhancement is expected to remain early for this part of the tumour. 
Probably contrast uptake enhancement can not differentiate between non­
responding and partial responding, but still malignant tissue. In this study there was 
no correlation between A tumour size and t0 values, possibly due to a still to low 
temporal resolution. In addition the evaluation of other contrast-enhancement 
parameters could be performed and compared before and after treatment. 
However, these require proper calibration. Furthermore, to avoid respiratory 
artefacts, breathing compensating techniques may be applied, which could improve 
dynamic imaging results.
19In conclusion, F MRS and dMRI of the liver were performed in a random group 
of patients with liver metastases of colorectal cancer, treated with weekly 5-FU
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bolus injections with the aim to uncover aspects of the uptake and metabolism of 
5-FU as well as the vascularisation of metastases. Patients were not selected for 
the presence of very large metastases close to the surface of the liver. The 
dMRI showed early rim contrast-enhancement of the liver metastases, indicating 
good vascularisation. This is a favourable condition for the uptake of 5-FU. The 
parameter onset of contrast-enhancement is unfortunately too imprecise to 
distinguish responders from non-responders in this relatively small study without 
complete responders. Correlations with response to treatment (volume of 
metastases in the field of the coil, t1/2 of 5-FU, Cmax of catabolites) were found
1Qwith F MRS, especially in the group with a larger contribution of the
1Q
metastases to the F MRS signal. However, these were less clear in the group 
with a smaller contribution of the metastases, probably because of a significant 
contribution of normal liver tissue to the observations. In further studies the 
selection of patients with specific location of metastases or the performance of
1Qlocalised F MRS appears to be inevitable [11,24].
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Chapter 8
Summary
Colorectal cancer is a major health problem. It is after breast and lung cancer the 
third most common cancer in the western world. In men it is the third most common 
malignant tumour after prostate and lung cancer, in women the second after breast 
cancer. Half of the patients with this disease will get metastases, especially in the 
liver, and die.
5-Fluorouracil or 5-FU is still the most important cytotoxic drug in the treatment of 
advanced colorectal cancer. In order to exert its effect 5-FU can be administered 
via different routes and can be given in combination with other drugs. However, in 
patients response percentages are only 15-20%. After a treatment period of several 
weeks or months normally conventional X-ray evaluation of the results is 
performed. In case of liver metastases a CT-scan or ultrasound investigation of the 
liver is carried out in order to compare tumour size before and after treatment. 
There are no parameters, which can predict response already at the start of the 
treatment. This response is dependent on the metabolism of 5-FU in the tumour. 
Although much is known about the 5-FU metabolism, many aspects remain to be 
solved.
The aim of the studies described in this thesis was to investigate the 
pharmacodynamics of 5-FU at the site of the tumour and the influence of the 
tumour vascularisation and perfusion on the metabolism of 5-FU. The techniques
19used were F magnetic resonance spectroscopy (MRS) and dynamic contrast-
19enhanced MR imaging (dMRI). F MRS provides information about the 
conversion of 5-FU in situ in the tumour in animals and in liver metastases in 
patients. This may reveal how the effect of treatment with 5-FU is achieved and 
provides the opportunity to study the effect of modulators on the metabolism of 5- 
FU. dMRI is an imaging technique which shows aspects of the vascularisation of 
the metastases. This information may be correlated with response to treatment.
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Chapter 1 of this thesis introduces the reader in the field of MR, including some
19basic principles and applications to biological systems. Especially F MRS of the 5- 
FU metabolism in colorectal cancer is discussed. An overview of the literature on
19F MRS studies using different in vitro and in vivo tumour models is given. 
Experimental approaches include MRS of cell lines, tumour extracts and in vivo 
studies on tumours in mice and patients.
Generally the outcome of these studies indicate that in in vitro studies and in in vivo
19studies in animals the sensitivity of the F MRS method is higher than in patient 
studies, because of the possibility to position the radiofrequency coil closer to the
19tissue of interest and to apply a higher 5-FU dose. Furthermore, in vitro F MRS
19investigations may show more details than in vivo F MRS, because samples are
19more homogeneous. However, the unique advantage of in vivo F MRS in animals 
or patients is the fact that the pharmacodynamics of 5-FU can be studied in the
19intact organism. An important question is whether F MRS is a powerful tool to 
correlate biological/therapeutic effects and metabolic data of 5-FU. A second
19question is whether F MRS can be correlated to visualizing the uptake of the 
contrast agent gadolinium diethylenetriaminepentaacetic acid (Gd-DTPA) in the 
tumour by dynamic MRI, thereby giving information about the vascularisation of the 
metastases.
After the introduction to the MRS technique in chapter 1, chapter 2 of the thesis 
gives an introduction to the state of the art on the treatment of colorectal cancer in 
men with 5-FU. Described are rationale and clinical results of frequently used 
treatment schedules. An overview of 5-FU metabolism is given. The use of 
biochemical modulators of 5-FU and different methods of administration of 5-FU 
are reviewed.
In chapter 3 the effect of modulators on 5-FU metabolite patterns in the murine
19C38 colon carcinoma determined by F MRS in vitro in tumour extracts is 
described. Tumour bearing mice were treated with 5-FU in combination with
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different modulators. Fifty minutes after 5-FU administration mice were sacrificed 
and the tumour was removed. Tumour extracts were prepared, which were
19investigated with F MRS. In the spectra of these tumour extracts 5-FU metabolite 
patterns could be distinguished. Except 5-FU, two main break down products 
(catabolites) and four distinct therapeutically active products (fluoronucleotides or 
anabolites) could be observed.
Using this experimental approach, the effect of the modulators methotrexate 
(MTX), a-interferon (IFN), W-(phosphonacetyl)-L-aspartate (PALA), and high and 
low dose leucovorin (LV) on 5-FU tumour metabolite patterns was investigated. A 
significant increase in the anabolite:catabolite ratio was observed for the groups 
treated with 5-FU in combination with the modulators MTX, a-IFN and high-dose 
LV, but not for the group treated with low-dose LV. A high anabolite:catabolite ratio 
means that there are relatively more active 5-FU components formed with a 
(cancer) cell killing effect than 5-FU break down products. Cotreatment with high­
dose PALA resulted in a significant decrease in the anabolite:catabolite ratio 
compared with treatment with 5-FU alone. Possible correlations of metabolite 
profiles with therapy response are discussed. Patient studies have shown that 
PALA has no effect as modulator of 5-FU, in contrast with other modulators. Our 
findings support these results.
19In chapter 4 F MRS studies on the 5-FU metabolite patterns in viable and 
necrotic tumour areas were presented of a colon carcinoma implanted 
subcutaneously in the mouse. Studies were performed on perchloric acid extracts 
of the viable and necrotic tumour fractions after 5-FU treatment.
19The F MR spectra exhibited resonances representing 5-FU, two catabolites, as 
well as several fluoronucleotide anabolites. The concentrations of anabolites and 
catabolites and the anabolite:catabolite ratio were significantly lower in the necrotic 
fraction than in the viable tumour fraction 50 minutes after administration of 5-FU, 
whereas the concentration of 5-FU was the same. Therefore, in 5-FU metabolism
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studies in tumours with MRS, it is important to consider the necrotic contribution to 
the tumour volume.
In chapter 5 the effect of carbogen gas (95% O2 and 5% CO2) on the 
pharmacodynamics of 5-FU in the murine C38 colon carcinoma is described. 
Carbogen breathing can influence tumour uptake of 5-FU by changes in tumour 
blood flow. Tumour bearing mice were treated with 5-FU with or without carbogen 
breathing. Increased levels of 5-FU and its anabolites and catabolites were found
19by sequential F MRS in the group treated with 5-FU in combination with carbogen 
compared with the group treated with 5-FU alone. The maximum amount of 5-FU 
and its metabolites, reached after treatment with 5-FU in combination with carbo­
gen breathing, was almost two-fold higher than after treatment with 5-FU alone. 
Despite these increased concentrations no significant effect of carbogen on growth 
inhibition of the tumour by 5-FU was observed.
In chapter 6 the results of 5-FU treatment on two different variants of the murine 
C26 colon carcinoma are reported. One variant (C26-B) is relatively insensitive to 
5-FU, whereas the other (C26-10) is sensitive. These two tumour variants were 
compared in vivo with respect to 5-FU uptake, retention and the metabolism of
195-FU using F MRS. Furthermore, the level of the target enzyme thymidylate 
synthase (TS), 5-FU incorporation into RNA and tumour growth were 
investigated. In addition, the effect of carbogen on 5-FU treatment was tested in 
these tumour models. Tumour bearing mice were treated with 5-FU alone or 
received 5-FU while breathing carbogen gas.
The C26-10 tumour showed a higher conversion of 5-FU to anabolites, which 
are responsible for the cytostatic effect of 5-FU, compared to the C26-B tumour. 
This result is reflected in a significantly greater tumour growth inhibition of the 
C26-10 tumour compared to the C26-B tumour. Addition of carbogen breathing 
did not affect the 5-FU metabolism, but did inhibit the tumour growth of the 5-FU 
treated C26-10 tumour compared to 5-FU alone. The activity of TS was
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significantly lower in the sensitive C26-10 tumours, while the inhibition of TS 
after 5-FU administration retained longer in this tumour than in the C26-B 
tumour. The increased sensitivity of the C26-10 tumour to 5-FU seems to be 
related to both increased accumulation of active 5-FU metabolites and 
enhanced inhibition of the target enzyme TS by 5-FU metabolites.
In chapter 7 finally a clinical study is presented in which patients with liver
19metastases of colorectal cancer treated with 5-FU were investigated by F MRS 
and dMRI of the liver. The purpose of this study was to examine the uptake and 
the metabolism of 5-FU in liver metastases of human colorectal cancer, as well 
as vascularisation of metastases. Patients were treated weekly with 5-FU. They 
were not selected for the presence of very large metastases.
In all patients the 19F MR spectrum of the liver showed a 5-FU and catabolite 
signal and in some spectra also anabolites were observed. Furthermore,
19correlations were found between F MRS parameters and response, especially 
in the patient group with larger metastases.
In these and other patients also dMRI was performed and the onset of contrast 
agent uptake of the liver metastases was determined.
Liver metastases showed increased uptake of contrast agent, indicating high 
vascularisation, but the onset of contrast agent uptake did not correlate with the
19response. This study shows that F MRS and dMRI can be performed in a 
random group of patients with liver metastases of colorectal cancer, not selected
19for size and position of the metastases. Correlations of F MRS parameters with 
treatment response were found, especially in the patient group with larger 
metastases. These correlations were less clear in the patient group with smaller 
metastases, probably because of significant contribution of normal liver tissue to 
the MRS signal.
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Future perspectives
19What have we learned from the results of the F MRS and dMRI experiments?
19F MRS gives the opportunity to investigate the metabolism of 5-FU in vitro and 
in vivo. This method gives more insight in the working mechanism of this widely 
used cytotoxic agent. It is a suitable technique to investigate the effects of new
19modulators of 5-FU. While F MRS on tumour extracts performed at high fields 
is more sensitive and gives more details than in vivo studies performed at lower
19fields, in vivo F MRS gives the opportunity to investigate non-invasively the 
pharmacodynamics of 5-FU in tumours in mice and men in situ. Preclinical 
studies in animals are directed to fundamental research, whereas investigations 
in patients are done in order to develop clinical studies with direct implications 
for the patient.
MRI with various contrast agents is an approach to study the vascularisation of a 
tumour or metastases. A prerequisite for the effectivity of chemotherapy is that 
the tumour is sufficiently perfused, so the cytotoxic agent can reach the tumour 
well. With contrast MRI the vascularisation and perfusion of the tumour and 
metastases can be visualised and this can be used to predict whether the drug
19will penetrate the tumour. Both experimental approaches, F MRS and contrast 
MRI, have their specific contribution to clarify the 5-FU pharmacokinetics and 
dynamics. The amount of drug reaching the tumour is important for its response 
to chemotherapy. Research will be directed towards an increased availability of
19the drug in the tumour by vaso-active drugs. F MRS as well as contrast MRI is 
essential to study this. In future studies we aim to improve these investigations of 
the pharmacodynamics of 5-FU. Finally, we hope to improve 5-FU containing 
treatment in patients with colorectal cancer as well as for other patient groups.
19Our research will also be directed to improve the F MRS and MRI techniques. 
Contrast MRI will be improved by employing other contrast agents such as 
superparamagnetic particles or gadolinium-albumin, by which together with 
perfusion and diffusion important aspects of tumour accessibility to 5-FU will be
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19uncovered. In F MRS studies of patients better localisation techniques and 
methods with higher sensitivity will be developed in order to separate signals of 
metastases from the surrounding normal liver tissue. Nowadays MRS is one of the 
few available methods to study non-invasively the pharmacodynamics of a drug.
19Of all MR-observable isotopes, F is perhaps the most convenient for studies of
19pharmacodynamics of drugs, because of the high intrinsic sensitivity of the F 
nucleus. This is important, because cytostatics and their metabolites are usually 
present in relatively low concentrations. The sensitivity is further increased
19because of the absence of background signals. Finally, the F nucleus is known 
to have a broad chemical shift range of about 500 ppm, reducing the chances of
19peak overlap. F MRS could be extended to studies with other drugs, which
19contain fluor atoms such as gemcitabine [1]. Another application of F MRS can
19be the introduction of fluorine labels into drugs lacking them [2]. Combining F 
MRS with physiological MRI approaches is a great challenge in order to extend 
the field of in vivo assessment of fluorinated drugs.
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Samenvatting en toekomst perspectief 
Samenvatting
Darmkanker is een belangrijk gezondheidsprobleem. Het is de derde meest 
voorkomende vorm van kanker in de westerse wereld na borstkanker en 
longkanker. Bij mannen is het de derde meest voorkomende vorm van 
kwaadaardige tumorgroei na prostaat- en longkanker, bij vrouwen de tweede na 
borstkanker. De helft van de patiënten zal uitzaaiingen (metastasen) krijgen, 
m.n. in de lever, en overlijden aan de ziekte.
5-Fluorouracil of 5-FU is nog steeds het belangrijkste medicijn bij de 
cytostatische behandeling van gevorderde stadia van darmkanker. Om het effect 
te vergroten kan 5-FU op verschillende manieren toegediend worden en ook 
gegeven worden in combinatie met andere medicijnen. Helaas reageert slechts 
15-20% van de patiënten op de behandeling met een verkleining van de tumor 
(respons). Normaal gesproken wordt na een behandelperiode van 2 tot 3 
maanden het effect van de chemotherapie beoordeeld met conventionele 
röntgenonderzoeken zoals het maken van een CT-scan of echografie. 
Vergeleken worden tumorgrootte vóór en na behandeling. Er bestaan geen 
parameters die bij aanvang van de behandeling het effect ervan kunnen 
voorspellen. Dit effect is afhankelijk van de stofwisseling (metabolisme) van 5- 
FU in de tumor. Ofschoon er al veel bekend is over het 5-FU metabolisme, zijn 
er nog een groot aantal aspecten die om opheldering vragen.
Het doel van de in dit proefschrift beschreven studies was het bestuderen van 
de werking en het metabolisme van 5-FU in de tumor. Hierbij spelen zowel 
farmacokinetiek (wat het lichaam doet met het medicijn) als farmacodynamiek 
(wat het medicijn doet met het lichaam) een rol. Onderwerp was ook de invloed 
van de tumordoorbloeding op de activiteit van 5-FU. De hierbij gebruikte
19technieken zijn 19-fluor magnetische resonantiespectroscopie ( F MRS) en
19dynamische magnetische resonantiebeeldvorming (imaging) (dMRI). F MRS is 
een methode die ons inzicht kan verschaffen in de omzetting van 5-FU ter
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plaatse van de tumor in proefdieren en in levermetastasen bij patiënten. Dit kan 
ons leren hoe het effect van de behandeling met 5-FU tot stand komt en geeft 
de mogelijkheid de werking van modulatoren op het 5-FU metabolisme te 
bestuderen. Met dMRI kan de bloedvoorziening van de uitzaaiingen in beeld 
gebracht worden. Deze informatie kan mogelijk gerelateerd worden aan het 
effect van de chemotherapie.
Hoofdstuk 1 van dit proefschrift introduceert de lezer in het gebied van de 
magnetische resonantie (MR). Beschreven worden enkele basisprincipes en
19toepassingen van MR in biologische systemen. Met name wordt 19F MRS van het 
5-FU-metabolisme bij darmkanker bediscussieerd. Er wordt een overzicht gegeven 
van de literatuur van verschillende tumormodellen: MRS van tumorcellen gekweekt 
in reageerbuizen of van extracten van tumoren (in vitro) of MRS in het levende 
organisme (in vivo) in proefdieren en in patiënten met levermetastasen.
19Over het algemeen is de gevoeligheid van de F MRS methode in diermodellen 
hoger dan in patiëntenstudies en in in vitro onderzoekingen hoger dan in vivo.
19Echter het grote voordeel van in vivo F MRS in proefdieren en patiënten is het feit 
dat de farmacodynamiek van 5-FU in het intacte organisme bestudeerd kan
19worden. Een belangrijke vraag is of F MRS een mogelijkheid kan bieden om het 
metabolisme van 5-FU te correleren met het effect van de behandeling in een
19vroeg stadium van de therapie. Een tweede vraag is of F MRS in vivo 
gecorreleerd kan worden met het zichtbaar maken van de opname van het 
contrastmiddel gadolinium diethylenetriaminepentaacetic acid (Gd-DTPA) in de 
tumor met behulp van de dynamische MRI, waardoor informatie kan worden 
verkregen over de bloedvoorziening van de tumor.
Na de inleiding over de MRS-techniek in hoofdstuk 1, geeft hoofdstuk 2 van het 
proefschrift een introductie over de stand van zaken betreffende de behandeling 
van darmkanker bij de mens met 5-FU. Beschreven worden de achtergronden en 
de klinische resultaten van veel gebruikte behandelingsschema’s. Er wordt een
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overzicht gegeven van het metabolisme van 5-FU, van de beïnvloeding van de 
resultaten van 5-FU door andere stoffen (modulatoren) en van verschillende 
methoden van toediening.
In hoofdstuk 3 wordt het effect beschreven van modulatoren op het 5-FU
19metabolisme, onderzocht met behulp van F MRS. Deze studie werd verricht aan 
extracten van tumoren van de C38 darmtumor bij de muis. Tumor dragende 
muizen werden behandeld met 5-FU in combinatie met verschillende modulatoren. 
Vijftig minuten na 5-FU toediening werden de muizen geofferd en werd de tumor 
verwijderd. Van de tumoren werden extracten vervaardigd, die onderzocht werden
19met F MRS. In de spectra van deze tumorextracten konden verschillende 
metabolieten onderscheiden worden. Behalve 5-FU zelf, werden twee belangrijke 
afbraakproducten (catabolieten) gezien en konden vier verschillende therapeutisch 
actieve producten (anabolieten) worden onderscheiden.
Met dit model werd het effect van de modulatoren methotrexaat (MTX), a-interferon 
(a-IFN), W-(phosphonacetyl)-L-aspartaat (PALA) en een hoge en lage dosis 
leucovorin (LV) op het 5-FU metabolisme onderzocht. Er werd een significante 
toename gezien van de anaboliet-cataboliet-ratio voor de groepen behandeld met 
5-FU in combinatie met de modulatoren MTX, a-IFN en hoge dosis LV, maar niet 
voor de groep behandeld met lage dosis LV. Een hoge anaboliet-cataboliet-ratio 
betekent dat er relatief meer actieve 5-FU componenten met een 
(kanker)celdodende werking worden gevormd dan 5-FU afbraakproducten. 
Behandeling in combinatie met PALA resulteerde in een significante afname van 
de anaboliet-cataboliet-ratio vergeleken met behandeling met 5-FU alleen. 
Mogelijke correlaties van deze resultaten met het effect van de behandeling 
worden bediscussieerd. Zo is uit patiëntenstudies gebleken dat PALA als 
modulator van 5-FU, in tegenstelling tot andere modulatoren, geen effect heeft. 
Onze resultaten ondersteunen deze bevindingen.
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In hoofdstuk 4 worden F MRS studies gepresenteerd over 5-FU 
metabolietpatronen van een onder de huid geïmplanteerde darmtumor bij de muis. 
Onderzocht werden extracten van levende (viabele) en afgestorven (necrotische) 
tumorfracties na behandeling met 5-FU.
19De F MR spectra lieten pieken zien van 5-FU, twee catabolieten en verschillende 
anabolieten. De absolute concentraties van anabolieten en catabolieten en de 
anaboliet-cataboliet-ratio waren significant lager in de necrotische fractie dan in de 
viabele tumorfractie gemeten 50 minuten na toediening van 5-FU, terwijl 
daarentegen de concentratie van 5-FU niet verschillend was. Daarom is het van 
belang in onderzoeken naar het 5-FU metabolisme in tumoren het aandeel necrose 
in beschouwing te nemen.
In hoofdstuk 5 wordt het effect beschreven van carbogeen gas (95% O2 en 5% 
CO2) op de farmacodynamiek van 5-FU in de C38 tumor bij de muis. Carbogeen 
beademing kan de opname van 5-FU in de tumor beïnvloeden door veranderingen 
in de bloedvoorziening van de tumor.
Tumor dragende muizen werden behandeld met 5-FU, al dan niet in combinatie
19met carbogeen-beademing. Met behulp van F MRS werd een verhoging van 5- 
FU en van de anabolieten en catabolieten gevonden in de groep behandeld met 5- 
FU in combinatie met carbogeen vergeleken met de groep behandeld met 5-FU 
alleen. Ondanks deze verhoging werd er geen remmend effect van carbogeen op 
de tumorgroei waargenomen.
In hoofdstuk 6 wordt het effect beschreven van 5-FU behandeling van twee 
verschillende varianten van de C26 darmtumor in de muis. De ene variant (C26- 
B) is relatief ongevoelig voor 5-FU, terwijl de andere (C26-10) gevoelig is. In 
deze twee tumorvarianten werden in vivo de 5-FU opname, de retentie en het
19metabolisme van 5-FU bestudeerd met behulp van F MRS. Ook werd de 
activiteit van het voor 5-FU behandeling belangrijke enzym thymidylaat 
synthase (TS) in deze tumoren gemeten en de tumorgroei vervolgd. Verder
19
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werd het effect van carbogeen op 5-FU behandeling in deze tumormodellen 
bekeken. In deze studie werden tumor dragende muizen behandeld met 5-FU 
alleen of met 5-FU plus carbogeen inhalatie.
De C26-10 tumor liet ten opzichte van de C26-B tumor een hogere omzetting 
zien van 5-FU in anabolieten, die verantwoordelijk zijn voor het 
(kanker)celdodende effect van 5-FU. Dit resultaat werd weerspiegeld in een 
significant hogere remming van de tumorgroei van de C26-10 tumor vergeleken 
met de C26-B tumor. Er werd geen effect van carbogeen op het 5-FU 
metabolisme gezien, maar carbogeen bleek wel de groei van de met 5-FU 
behandelde C26-10 tumor af te remmen. De activiteit van TS was significant 
lager in de gevoelige C26-10 tumoren, terwijl de remming van TS na 5-FU 
toediening langer behouden bleef in deze tumor dan in de C26-B tumor. De 
verhoogde gevoeligheid van de C26-10 tumor voor 5-FU lijkt gerelateerd aan 
enerzijds verhoogde omzetting van 5-FU in actieve 5-FU metabolieten en 
anderzijds toegenomen remming van het enzym TS door 5-FU metabolieten.
In hoofdstuk 7 wordt tenslotte een studie gepresenteerd waarin patiënten met 
levermetastasen van darmkanker, die behandeld werden met 5-FU, onderzocht
19werden met F MRS en dMRI van de lever. Het doel van het onderzoek was de 
opname en het metabolisme van 5-FU in levermetastasen te bestuderen, evenals 
de bloedvoorziening van de metastasen. Patiënten werden wekelijks behandeld 
met 5-FU.
19Bij alle patiënten werd in de F MR spectra van de lever een 5-FU- en 
catabolietensignaal gezien en in spectra van sommige patiënten waren ook
19anabolieten zichtbaar. Er werden bovendien correlaties gevonden tussen F MRS 
parameters en respons, vooral in de groep patiënten met grotere metastasen.
In deze en andere patiënten werd eveneens dMRI verricht, waarbij het tijdstip van 
aankleuring van de metastasen bepaald werd. Levermetastasen vertoonden 
verhoogde contrastopname, wijzend op een goede bloedvoorziening, maar het 
tijdstip van aankleuring correleerde niet met de respons. Deze studie laat zien dat
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F MRS en dMRI verricht kunnen worden in een groep patiënten met 
levermetastasen, niet-geselecteerd op grootte en ligging van de metastasen.
19Correlaties van F MRS parameters met respons op behandeling werden 
gevonden, vooral in de groep patiënten met grotere metastasen. Deze correlaties 
waren minder duidelijk in de groep patiënten met kleinere metastasen, 
waarschijnlijk ten gevolge van een significante bijdrage van het normale 
leverweefsel aan het MRS-signaal.
Toekomst perspectief
19 19Wat hebben we geleerd van de F MRS en dMRI experimenten? F MRS biedt 
mogelijkheden voor onderzoek naar het metabolisme van 5-FU in vitro en in 
vivo. Deze methode geeft meer inzicht in de werking van dit veel gebruikte 
cytostaticum. Het is een uitermate geschikte techniek om de effecten van 
nieuwe modulatoren van 5-FU te bestuderen. Terwijl het onderzoek aan 
tumorextracten, uitgevoerd bij hogere veldsterkte, gevoeliger is en meer details 
laat zien dan in vivo onderzoek, uitgevoerd bij lagere veldsterkte, biedt in vivo
1919F MRS de mogelijkheid op niet-invasieve wijze de farmacodynamiek van 5-FU 
in tumoren bij mens en dier in situ te bestuderen. Preklinische studies bij 
proefdieren zijn gericht op fundamenteel onderzoek, terwijl bij patiënten 
onderzoek wordt gedaan om klinische studies te ontwikkelen met een direct 
belang voor de patiënt.
MRI met verschillende contrastmiddelen is een manier om de bloedvoorziening van 
de tumor of metastasen te bestuderen. Een voorwaarde voor de effectiviteit van 
chemotherapie is dat de tumor voldoende doorbloed wordt, zodat het cytostaticum 
goed in de tumor kan komen. Met contrast MRI kan zichtbaar gemaakt worden hoe 
de bloedvoorziening en bloeddoorstroming in de tumor of metastasen is en 
contrast MRI kan gebruikt worden om te voorspellen of het geneesmiddel in de
19tumor zal doordringen. Beide experimentele benaderingen, F MRS en contrast 
MRI, hebben hun specifieke bijdrage in het ophelderen van de farmacodynamiek 
van 5-FU. De hoeveelheid medicijn die de tumor bereikt is van belang voor de
19
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respons op chemotherapie. Onderzoek zal gefocust worden op een verhoogde 
beschikbaarheid van het medicijn in de tumor met behulp van vaso-actieve stoffen.
19Zowel F MRS als contrast MRI zijn van belang om dit te bestuderen. In 
toekomstige studies streven wij ernaar dit onderzoek naar de farmacodynamiek 
van 5-FU verder te verbeteren. Uiteindelijk hopen wij de behandeling met 5-FU 
voor patiënten met colorectale kanker te kunnen verbeteren, evenals voor andere 
patiëntengroepen.
19Ons onderzoek zal ook gericht worden op het verbeteren van F MRS en MRI 
technieken. Contrast MRI zal verbeterd worden door andere contrastmiddelen te 
gebruiken zoals superparamagnetische partikels of gadolinium-albumine, waardoor 
tegelijk met perfusie en diffusie belangrijke aspecten van tumortoegankelijkheid 
voor 5-FU opgehelderd zullen worden. Er zullen betere lokalisatietechnieken
19ontwikkeld worden en methodes met hogere sensitiviteit voor F MRS 
patiëntenstudies, zodat de signalen van de metastasen onderscheiden kunnen 
worden van het omgevende normale leverweefsel. Momenteel is MRS een van de 
weinige beschikbare methodes om niet-invasief de farmacodynamiek van een
19geneesmiddel te bestuderen. Van alle MR-zichtbare isotopen is F mogelijk het 
meest geschikt voor studies van farmacodynamiek van geneesmiddelen vanwege 
zijn hoge intrinsieke gevoeligheid. Dit is van belang, omdat cytostatica en hun 
metabolieten meestal in relatief lage concentraties aanwezig zijn. Verder wordt de 
gevoeligheid verbeterd door de afwezigheid van achtergrondsignalen. Tenslotte
19heeft de F nucleus een brede band van chemische verschuiving van ongeveer
19500 ppm, waardoor de kans op overlap van pieken relatief klein is. F MRS zou 
uitgebreid kunnen worden naar studies met andere geneesmiddelen die
19fluoratomen bevatten, zoals gemcitabine. Een andere toepassing van F MRS kan 
zijn het inbouwen van fluorlabels in medicijnen die deze missen. Het is een grote
19uitdaging om F MRS te combineren met fysiologische MRI toepassingen en zo 
het veld van in vivo onderzoek van gefluorineerde geneesmiddelen uit te breiden.
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